#sarbecovirus — Public Fediverse posts

Cross-clade #vaccination to overcome #sarbecovirus or #merbecovirus #neutralization gaps, https://etidiohnew.blogspot.com/2026/06/cross-clade-vaccination-to-overcome.html

Cross-clade #vaccination to overcome #sarbecovirus or #merbecovirus #neutralization gaps, https://etidiohnew.blogspot.com/2026/06/cross-clade-vaccination-to-overcome.html

Cross-clade #vaccination to overcome #sarbecovirus or #merbecovirus #neutralization gaps, https://etidiohnew.blogspot.com/2026/06/cross-clade-vaccination-to-overcome.html

Cross-clade #vaccination to overcome #sarbecovirus or #merbecovirus #neutralization gaps, https://etidiohnew.blogspot.com/2026/06/cross-clade-vaccination-to-overcome.html

Cross-clade #vaccination to overcome #sarbecovirus or #merbecovirus #neutralization gaps, https://etidiohnew.blogspot.com/2026/06/cross-clade-vaccination-to-overcome.html

Re-infection with #SARS-CoV-2 is associated with increased #antibody breadth and potency against diverse #sarbecovirus strains, https://etidiohnew.blogspot.com/2026/02/re-infection-with-sars-cov-2-is.html

Re-infection with #SARS-CoV-2 is associated with increased #antibody breadth and potency against diverse #sarbecovirus strains, https://etidiohnew.blogspot.com/2026/02/re-infection-with-sars-cov-2-is.html

Re-infection with #SARS-CoV-2 is associated with increased #antibody breadth and potency against diverse #sarbecovirus strains, https://etidiohnew.blogspot.com/2026/02/re-infection-with-sars-cov-2-is.html

Re-infection with #SARS-CoV-2 is associated with increased #antibody breadth and potency against diverse #sarbecovirus strains, https://etidiohnew.blogspot.com/2026/02/re-infection-with-sars-cov-2-is.html

Re-infection with #SARS-CoV-2 is associated with increased #antibody breadth and potency against diverse #sarbecovirus strains, https://etidiohnew.blogspot.com/2026/02/re-infection-with-sars-cov-2-is.html

#Bat #sarbecovirus WIV1-CoV bears an adaptive #mutation that alters #spike dynamics and enhances #ACE2 binding, https://etidiohnew.blogspot.com/2025/10/bat-sarbecovirus-wiv1-cov-bears.html

#Bat #sarbecovirus WIV1-CoV bears an adaptive #mutation that alters #spike dynamics and enhances #ACE2 binding, https://etidiohnew.blogspot.com/2025/10/bat-sarbecovirus-wiv1-cov-bears.html

#Bat #sarbecovirus WIV1-CoV bears an adaptive #mutation that alters #spike dynamics and enhances #ACE2 binding, https://etidiohnew.blogspot.com/2025/10/bat-sarbecovirus-wiv1-cov-bears.html

#Bat #sarbecovirus WIV1-CoV bears an adaptive #mutation that alters #spike dynamics and enhances #ACE2 binding, https://etidiohnew.blogspot.com/2025/10/bat-sarbecovirus-wiv1-cov-bears.html

#Bat #sarbecovirus WIV1-CoV bears an adaptive #mutation that alters #spike dynamics and enhances #ACE2 binding, https://etidiohnew.blogspot.com/2025/10/bat-sarbecovirus-wiv1-cov-bears.html

Broadly #Sarbecovirus-Neutralizing #Antibodies Induced by Ancestral #SARS-CoV-2 #Infection, https://etidiohnew.blogspot.com/2025/09/broadly-sarbecovirus-neutralizing.html

Broadly #Sarbecovirus-Neutralizing #Antibodies Induced by Ancestral #SARS-CoV-2 #Infection, https://etidiohnew.blogspot.com/2025/09/broadly-sarbecovirus-neutralizing.html

Broadly #Sarbecovirus-Neutralizing #Antibodies Induced by Ancestral #SARS-CoV-2 #Infection, https://etidiohnew.blogspot.com/2025/09/broadly-sarbecovirus-neutralizing.html

Broadly #Sarbecovirus-Neutralizing #Antibodies Induced by Ancestral #SARS-CoV-2 #Infection, https://etidiohnew.blogspot.com/2025/09/broadly-sarbecovirus-neutralizing.html

Broadly #Sarbecovirus-Neutralizing #Antibodies Induced by Ancestral #SARS-CoV-2 #Infection, https://etidiohnew.blogspot.com/2025/09/broadly-sarbecovirus-neutralizing.html

#Bat #sarbecovirus WIV1-CoV bears an adaptive #mutation that alters spike dynamics and enhances #ACE2 binding, https://etidiohnew.blogspot.com/2025/04/bat-sarbecovirus-wiv1-cov-bears.html

#Bat #sarbecovirus WIV1-CoV bears an adaptive #mutation that alters spike dynamics and enhances #ACE2 binding, https://etidiohnew.blogspot.com/2025/04/bat-sarbecovirus-wiv1-cov-bears.html

#Bat #sarbecovirus WIV1-CoV bears an adaptive #mutation that alters spike dynamics and enhances #ACE2 binding, https://etidiohnew.blogspot.com/2025/04/bat-sarbecovirus-wiv1-cov-bears.html

#Bat #sarbecovirus WIV1-CoV bears an adaptive #mutation that alters spike dynamics and enhances #ACE2 binding, https://etidiohnew.blogspot.com/2025/04/bat-sarbecovirus-wiv1-cov-bears.html

#Bat #sarbecovirus WIV1-CoV bears an adaptive #mutation that alters spike dynamics and enhances #ACE2 binding, https://etidiohnew.blogspot.com/2025/04/bat-sarbecovirus-wiv1-cov-bears.html

A trivalent #mucosal #vaccine encoding phylogenetically inferred ancestral #RBD #sequences confers pan- #Sarbecovirus #protection in mice https://www.cell.com/cell-host-microbe/fulltext/S1931-3128(24)00403-7?rss=yes

Case et al. use ancestral phylogenetic reconstructions of Sarbecovirus sequences to generate a pan-Sarbecovirus vaccine. In mice, vaccine confers protection vs all tested Sarbecoviruses, including #SARS-CoV, multiple SARS-CoV-2 #variants, & pre-emergent Sarbecovirus strains.

A trivalent #mucosal #vaccine encoding phylogenetically inferred ancestral #RBD #sequences confers pan- #Sarbecovirus #protection in mice https://www.cell.com/cell-host-microbe/fulltext/S1931-3128(24)00403-7?rss=yes

Case et al. use ancestral phylogenetic reconstructions of Sarbecovirus sequences to generate a pan-Sarbecovirus vaccine. In mice, vaccine confers protection vs all tested Sarbecoviruses, including #SARS-CoV, multiple SARS-CoV-2 #variants, & pre-emergent Sarbecovirus strains.

A trivalent #mucosal #vaccine encoding phylogenetically inferred ancestral #RBD #sequences confers pan- #Sarbecovirus #protection in mice https://www.cell.com/cell-host-microbe/fulltext/S1931-3128(24)00403-7?rss=yes

Case et al. use ancestral phylogenetic reconstructions of Sarbecovirus sequences to generate a pan-Sarbecovirus vaccine. In mice, vaccine confers protection vs all tested Sarbecoviruses, including #SARS-CoV, multiple SARS-CoV-2 #variants, & pre-emergent Sarbecovirus strains.

A trivalent #mucosal #vaccine encoding phylogenetically inferred ancestral #RBD #sequences confers pan- #Sarbecovirus #protection in mice https://www.cell.com/cell-host-microbe/fulltext/S1931-3128(24)00403-7?rss=yes

Case et al. use ancestral phylogenetic reconstructions of Sarbecovirus sequences to generate a pan-Sarbecovirus vaccine. In mice, vaccine confers protection vs all tested Sarbecoviruses, including #SARS-CoV, multiple SARS-CoV-2 #variants, & pre-emergent Sarbecovirus strains.

A trivalent #mucosal #vaccine encoding phylogenetically inferred ancestral #RBD #sequences confers pan- #Sarbecovirus #protection in mice https://www.cell.com/cell-host-microbe/fulltext/S1931-3128(24)00403-7?rss=yes

Case et al. use ancestral phylogenetic reconstructions of Sarbecovirus sequences to generate a pan-Sarbecovirus vaccine. In mice, vaccine confers protection vs all tested Sarbecoviruses, including #SARS-CoV, multiple SARS-CoV-2 #variants, & pre-emergent Sarbecovirus strains.

#Coronavirus Disease Research #References (by AMEDEO, December 7 ’24)

1. VASSILOPOULOS S, Mylonakis E
   After COVID-19 diagnosis, risk for incident type 2 diabetes was elevated for up to 2 y.
   Ann Intern Med. 2024 Dec 3. doi: 10.7326/ANNALS-24-02887.
   PubMed         Abstract available

   Antiviral Res

2. SCHRELL L, Fuchs HL, Dickmanns A, Scheibner D, et al
   Inhibitors of dihydroorotate dehydrogenase synergize with the broad antiviral activity of 4′-fluorouridine.
   Antiviral Res. 2024 Dec 3:106046. doi: 10.1016/j.antiviral.2024.106046.
   PubMed         Abstract available

   Br J Anaesth

3. SPARLING JL, Chitilian HV, Korn E, Alfille PH, et al
   Induction of anaesthesia and airway management in patients with severe tracheal stenosis: a single-centre retrospective study.
   Br J Anaesth. 2024 Dec 4:S0007-0912(24)00667-6. doi: 10.1016/j.bja.2024.
   PubMed        

   Emerg Infect Dis

4. HASSAN AM, Muhlemann B, Al-Subhi TL, Rodon J, et al
   Ongoing Evolution of Middle East Respiratory Syndrome Coronavirus, Saudi Arabia, 2023-2024.
   Emerg Infect Dis. 2024;31.
   PubMed         Abstract available

   Infect Control Hosp Epidemiol

5. KIM T, Moehring RW, Turner NA, Ashley ED, et al
   Long-term trends in the incidence of hospital-acquired carbapenem-resistant Enterobacterales and antimicrobial utilization in a network of community hospitals in the Southeastern United States from 2013 to 2023.
   Infect Control Hosp Epidemiol. 2024 Dec 3:1-7. doi: 10.1017/ice.2024.
   PubMed         Abstract available
6. USIAK S, Aslam A, Yan J, Madhavappallil J, et al
   Utility of post-admission SARS-CoV-2 serial testing in hospitalized patients with cancer.
   Infect Control Hosp Epidemiol. 2024 Dec 3:1-3. doi: 10.1017/ice.2024.
   PubMed         Abstract available
7. PASSARETTI CL, Bischoff W, Chan J, Diekema DJ, et al
   Respiratory equality: let’s stop playing favorites with COVID-19 in the healthcare setting.
   Infect Control Hosp Epidemiol. 2024 Dec 4:1-2. doi: 10.1017/ice.2024.
   PubMed        

   Int J Infect Dis

8. IP B, Pan S, Yao A, Lau L, et al
   COVID-19 vaccination and cerebral small vessel disease progression – A prospective cohort study.
   Int J Infect Dis. 2024 Dec 3:107324. doi: 10.1016/j.ijid.2024.107324.
   PubMed         Abstract available

   J Infect

9. PENG Y, Shen H, Zhang Y, Zeng S, et al
   A comprehensive pan-cancer analysis of SARS-CoV-2-related cancer malignancy: COVID-19 infection shapes a dynamic immune microenvironment and affects the prognosis.
   J Infect. 2024 Nov 30:106364. doi: 10.1016/j.jinf.2024.106364.
   PubMed        

   J Med Virol

10. ZWYGART AC, Medaglia C, Zhu Y, Bart Tarbet E, et al
    Development of Broad-Spectrum beta-Cyclodextrins-Based Nanomaterials Against Influenza Viruses.
    J Med Virol. 2024;96:e70101.
    PubMed         Abstract available
11. STICH M, Magalhaes VG, Burger F, Garbade SF, et al
    Elevated Soluble ACE2 Activity in Children and Adults After SARS-CoV-2 Exposure Irrespective of Laboratory-Confirmed Infection.
    J Med Virol. 2024;96:e70098.
    PubMed         Abstract available
12. MAIMAITI M, Kong L, Yu Q, Wang Z, et al
    Analytical Performance of a Novel Nanopore Sequencing for SARS-CoV-2 Genomic Surveillance.
    J Med Virol. 2024;96:e70108.
    PubMed         Abstract available

    J Virol

13. ZUO F, Cao Y, Sun R, Wang Q, et al
    Ultrapotent IgA dimeric antibodies neutralize emerging Omicron variants.
    J Virol. 2024 Dec 4:e0174024. doi: 10.1128/jvi.01740.
    PubMed        
14. ZHANG Y, Zhang N, Zhang Y, Li Y, et al
    Potassium molybdate blocks APN-dependent coronavirus entry by degrading receptor via PIK3C3-mediated autophagy.
    J Virol. 2024 Dec 6:e0144924. doi: 10.1128/jvi.01449.
    PubMed         Abstract available

    JAMA

15. ANDERER S
    CDC Recommends Second COVID-19 Vaccine Dose for Older Adults.
    JAMA. 2024 Dec 6. doi: 10.1001/jama.2024.24258.
    PubMed        

    Nature

16. KUDIABOR H
    Virtual lab powered by ‘AI scientists’ super-charges biomedical research.
    Nature. 2024 Dec 4. doi: 10.1038/d41586-024-01684.
    PubMed        

    Science

17. KAISER J
    Trump picks an ‘outsider’ and NIH critic to lead agency.
    Science. 2024;386:1080-1081.
    PubMed         Abstract available

#betacoronavirus #covid #COVID19 #health #mentalHealth #research #sarbecovirus #sarsCov2 #science

#Coronavirus Disease Research #References (by AMEDEO, December 7 ’24)

1. VASSILOPOULOS S, Mylonakis E
   After COVID-19 diagnosis, risk for incident type 2 diabetes was elevated for up to 2 y.
   Ann Intern Med. 2024 Dec 3. doi: 10.7326/ANNALS-24-02887.
   PubMed         Abstract available

   Antiviral Res

2. SCHRELL L, Fuchs HL, Dickmanns A, Scheibner D, et al
   Inhibitors of dihydroorotate dehydrogenase synergize with the broad antiviral activity of 4′-fluorouridine.
   Antiviral Res. 2024 Dec 3:106046. doi: 10.1016/j.antiviral.2024.106046.
   PubMed         Abstract available

   Br J Anaesth

3. SPARLING JL, Chitilian HV, Korn E, Alfille PH, et al
   Induction of anaesthesia and airway management in patients with severe tracheal stenosis: a single-centre retrospective study.
   Br J Anaesth. 2024 Dec 4:S0007-0912(24)00667-6. doi: 10.1016/j.bja.2024.
   PubMed        

   Emerg Infect Dis

4. HASSAN AM, Muhlemann B, Al-Subhi TL, Rodon J, et al
   Ongoing Evolution of Middle East Respiratory Syndrome Coronavirus, Saudi Arabia, 2023-2024.
   Emerg Infect Dis. 2024;31.
   PubMed         Abstract available

   Infect Control Hosp Epidemiol

5. KIM T, Moehring RW, Turner NA, Ashley ED, et al
   Long-term trends in the incidence of hospital-acquired carbapenem-resistant Enterobacterales and antimicrobial utilization in a network of community hospitals in the Southeastern United States from 2013 to 2023.
   Infect Control Hosp Epidemiol. 2024 Dec 3:1-7. doi: 10.1017/ice.2024.
   PubMed         Abstract available
6. USIAK S, Aslam A, Yan J, Madhavappallil J, et al
   Utility of post-admission SARS-CoV-2 serial testing in hospitalized patients with cancer.
   Infect Control Hosp Epidemiol. 2024 Dec 3:1-3. doi: 10.1017/ice.2024.
   PubMed         Abstract available
7. PASSARETTI CL, Bischoff W, Chan J, Diekema DJ, et al
   Respiratory equality: let’s stop playing favorites with COVID-19 in the healthcare setting.
   Infect Control Hosp Epidemiol. 2024 Dec 4:1-2. doi: 10.1017/ice.2024.
   PubMed        

   Int J Infect Dis

8. IP B, Pan S, Yao A, Lau L, et al
   COVID-19 vaccination and cerebral small vessel disease progression – A prospective cohort study.
   Int J Infect Dis. 2024 Dec 3:107324. doi: 10.1016/j.ijid.2024.107324.
   PubMed         Abstract available

   J Infect

9. PENG Y, Shen H, Zhang Y, Zeng S, et al
   A comprehensive pan-cancer analysis of SARS-CoV-2-related cancer malignancy: COVID-19 infection shapes a dynamic immune microenvironment and affects the prognosis.
   J Infect. 2024 Nov 30:106364. doi: 10.1016/j.jinf.2024.106364.
   PubMed        

   J Med Virol

10. ZWYGART AC, Medaglia C, Zhu Y, Bart Tarbet E, et al
    Development of Broad-Spectrum beta-Cyclodextrins-Based Nanomaterials Against Influenza Viruses.
    J Med Virol. 2024;96:e70101.
    PubMed         Abstract available
11. STICH M, Magalhaes VG, Burger F, Garbade SF, et al
    Elevated Soluble ACE2 Activity in Children and Adults After SARS-CoV-2 Exposure Irrespective of Laboratory-Confirmed Infection.
    J Med Virol. 2024;96:e70098.
    PubMed         Abstract available
12. MAIMAITI M, Kong L, Yu Q, Wang Z, et al
    Analytical Performance of a Novel Nanopore Sequencing for SARS-CoV-2 Genomic Surveillance.
    J Med Virol. 2024;96:e70108.
    PubMed         Abstract available

    J Virol

13. ZUO F, Cao Y, Sun R, Wang Q, et al
    Ultrapotent IgA dimeric antibodies neutralize emerging Omicron variants.
    J Virol. 2024 Dec 4:e0174024. doi: 10.1128/jvi.01740.
    PubMed        
14. ZHANG Y, Zhang N, Zhang Y, Li Y, et al
    Potassium molybdate blocks APN-dependent coronavirus entry by degrading receptor via PIK3C3-mediated autophagy.
    J Virol. 2024 Dec 6:e0144924. doi: 10.1128/jvi.01449.
    PubMed         Abstract available

    JAMA

15. ANDERER S
    CDC Recommends Second COVID-19 Vaccine Dose for Older Adults.
    JAMA. 2024 Dec 6. doi: 10.1001/jama.2024.24258.
    PubMed        

    Nature

16. KUDIABOR H
    Virtual lab powered by ‘AI scientists’ super-charges biomedical research.
    Nature. 2024 Dec 4. doi: 10.1038/d41586-024-01684.
    PubMed        

    Science

17. KAISER J
    Trump picks an ‘outsider’ and NIH critic to lead agency.
    Science. 2024;386:1080-1081.
    PubMed         Abstract available

#betacoronavirus #covid #COVID19 #health #mentalHealth #research #sarbecovirus #sarsCov2 #science

#Coronavirus Disease Research #References (by AMEDEO, December 7 ’24)

1. VASSILOPOULOS S, Mylonakis E
   After COVID-19 diagnosis, risk for incident type 2 diabetes was elevated for up to 2 y.
   Ann Intern Med. 2024 Dec 3. doi: 10.7326/ANNALS-24-02887.
   PubMed         Abstract available

   Antiviral Res

2. SCHRELL L, Fuchs HL, Dickmanns A, Scheibner D, et al
   Inhibitors of dihydroorotate dehydrogenase synergize with the broad antiviral activity of 4′-fluorouridine.
   Antiviral Res. 2024 Dec 3:106046. doi: 10.1016/j.antiviral.2024.106046.
   PubMed         Abstract available

   Br J Anaesth

3. SPARLING JL, Chitilian HV, Korn E, Alfille PH, et al
   Induction of anaesthesia and airway management in patients with severe tracheal stenosis: a single-centre retrospective study.
   Br J Anaesth. 2024 Dec 4:S0007-0912(24)00667-6. doi: 10.1016/j.bja.2024.
   PubMed        

   Emerg Infect Dis

4. HASSAN AM, Muhlemann B, Al-Subhi TL, Rodon J, et al
   Ongoing Evolution of Middle East Respiratory Syndrome Coronavirus, Saudi Arabia, 2023-2024.
   Emerg Infect Dis. 2024;31.
   PubMed         Abstract available

   Infect Control Hosp Epidemiol

5. KIM T, Moehring RW, Turner NA, Ashley ED, et al
   Long-term trends in the incidence of hospital-acquired carbapenem-resistant Enterobacterales and antimicrobial utilization in a network of community hospitals in the Southeastern United States from 2013 to 2023.
   Infect Control Hosp Epidemiol. 2024 Dec 3:1-7. doi: 10.1017/ice.2024.
   PubMed         Abstract available
6. USIAK S, Aslam A, Yan J, Madhavappallil J, et al
   Utility of post-admission SARS-CoV-2 serial testing in hospitalized patients with cancer.
   Infect Control Hosp Epidemiol. 2024 Dec 3:1-3. doi: 10.1017/ice.2024.
   PubMed         Abstract available
7. PASSARETTI CL, Bischoff W, Chan J, Diekema DJ, et al
   Respiratory equality: let’s stop playing favorites with COVID-19 in the healthcare setting.
   Infect Control Hosp Epidemiol. 2024 Dec 4:1-2. doi: 10.1017/ice.2024.
   PubMed        

   Int J Infect Dis

8. IP B, Pan S, Yao A, Lau L, et al
   COVID-19 vaccination and cerebral small vessel disease progression – A prospective cohort study.
   Int J Infect Dis. 2024 Dec 3:107324. doi: 10.1016/j.ijid.2024.107324.
   PubMed         Abstract available

   J Infect

9. PENG Y, Shen H, Zhang Y, Zeng S, et al
   A comprehensive pan-cancer analysis of SARS-CoV-2-related cancer malignancy: COVID-19 infection shapes a dynamic immune microenvironment and affects the prognosis.
   J Infect. 2024 Nov 30:106364. doi: 10.1016/j.jinf.2024.106364.
   PubMed        

   J Med Virol

10. ZWYGART AC, Medaglia C, Zhu Y, Bart Tarbet E, et al
    Development of Broad-Spectrum beta-Cyclodextrins-Based Nanomaterials Against Influenza Viruses.
    J Med Virol. 2024;96:e70101.
    PubMed         Abstract available
11. STICH M, Magalhaes VG, Burger F, Garbade SF, et al
    Elevated Soluble ACE2 Activity in Children and Adults After SARS-CoV-2 Exposure Irrespective of Laboratory-Confirmed Infection.
    J Med Virol. 2024;96:e70098.
    PubMed         Abstract available
12. MAIMAITI M, Kong L, Yu Q, Wang Z, et al
    Analytical Performance of a Novel Nanopore Sequencing for SARS-CoV-2 Genomic Surveillance.
    J Med Virol. 2024;96:e70108.
    PubMed         Abstract available

    J Virol

13. ZUO F, Cao Y, Sun R, Wang Q, et al
    Ultrapotent IgA dimeric antibodies neutralize emerging Omicron variants.
    J Virol. 2024 Dec 4:e0174024. doi: 10.1128/jvi.01740.
    PubMed        
14. ZHANG Y, Zhang N, Zhang Y, Li Y, et al
    Potassium molybdate blocks APN-dependent coronavirus entry by degrading receptor via PIK3C3-mediated autophagy.
    J Virol. 2024 Dec 6:e0144924. doi: 10.1128/jvi.01449.
    PubMed         Abstract available

    JAMA

15. ANDERER S
    CDC Recommends Second COVID-19 Vaccine Dose for Older Adults.
    JAMA. 2024 Dec 6. doi: 10.1001/jama.2024.24258.
    PubMed        

    Nature

16. KUDIABOR H
    Virtual lab powered by ‘AI scientists’ super-charges biomedical research.
    Nature. 2024 Dec 4. doi: 10.1038/d41586-024-01684.
    PubMed        

    Science

17. KAISER J
    Trump picks an ‘outsider’ and NIH critic to lead agency.
    Science. 2024;386:1080-1081.
    PubMed         Abstract available

#betacoronavirus #covid #COVID19 #health #mentalHealth #research #sarbecovirus #sarsCov2 #science

#Coronavirus Disease Research #References (by AMEDEO, December 7 ’24)

1. VASSILOPOULOS S, Mylonakis E
   After COVID-19 diagnosis, risk for incident type 2 diabetes was elevated for up to 2 y.
   Ann Intern Med. 2024 Dec 3. doi: 10.7326/ANNALS-24-02887.
   PubMed         Abstract available

   Antiviral Res

2. SCHRELL L, Fuchs HL, Dickmanns A, Scheibner D, et al
   Inhibitors of dihydroorotate dehydrogenase synergize with the broad antiviral activity of 4′-fluorouridine.
   Antiviral Res. 2024 Dec 3:106046. doi: 10.1016/j.antiviral.2024.106046.
   PubMed         Abstract available

   Br J Anaesth

3. SPARLING JL, Chitilian HV, Korn E, Alfille PH, et al
   Induction of anaesthesia and airway management in patients with severe tracheal stenosis: a single-centre retrospective study.
   Br J Anaesth. 2024 Dec 4:S0007-0912(24)00667-6. doi: 10.1016/j.bja.2024.
   PubMed        

   Emerg Infect Dis

4. HASSAN AM, Muhlemann B, Al-Subhi TL, Rodon J, et al
   Ongoing Evolution of Middle East Respiratory Syndrome Coronavirus, Saudi Arabia, 2023-2024.
   Emerg Infect Dis. 2024;31.
   PubMed         Abstract available

   Infect Control Hosp Epidemiol

5. KIM T, Moehring RW, Turner NA, Ashley ED, et al
   Long-term trends in the incidence of hospital-acquired carbapenem-resistant Enterobacterales and antimicrobial utilization in a network of community hospitals in the Southeastern United States from 2013 to 2023.
   Infect Control Hosp Epidemiol. 2024 Dec 3:1-7. doi: 10.1017/ice.2024.
   PubMed         Abstract available
6. USIAK S, Aslam A, Yan J, Madhavappallil J, et al
   Utility of post-admission SARS-CoV-2 serial testing in hospitalized patients with cancer.
   Infect Control Hosp Epidemiol. 2024 Dec 3:1-3. doi: 10.1017/ice.2024.
   PubMed         Abstract available
7. PASSARETTI CL, Bischoff W, Chan J, Diekema DJ, et al
   Respiratory equality: let’s stop playing favorites with COVID-19 in the healthcare setting.
   Infect Control Hosp Epidemiol. 2024 Dec 4:1-2. doi: 10.1017/ice.2024.
   PubMed        

   Int J Infect Dis

8. IP B, Pan S, Yao A, Lau L, et al
   COVID-19 vaccination and cerebral small vessel disease progression – A prospective cohort study.
   Int J Infect Dis. 2024 Dec 3:107324. doi: 10.1016/j.ijid.2024.107324.
   PubMed         Abstract available

   J Infect

9. PENG Y, Shen H, Zhang Y, Zeng S, et al
   A comprehensive pan-cancer analysis of SARS-CoV-2-related cancer malignancy: COVID-19 infection shapes a dynamic immune microenvironment and affects the prognosis.
   J Infect. 2024 Nov 30:106364. doi: 10.1016/j.jinf.2024.106364.
   PubMed        

   J Med Virol

10. ZWYGART AC, Medaglia C, Zhu Y, Bart Tarbet E, et al
    Development of Broad-Spectrum beta-Cyclodextrins-Based Nanomaterials Against Influenza Viruses.
    J Med Virol. 2024;96:e70101.
    PubMed         Abstract available
11. STICH M, Magalhaes VG, Burger F, Garbade SF, et al
    Elevated Soluble ACE2 Activity in Children and Adults After SARS-CoV-2 Exposure Irrespective of Laboratory-Confirmed Infection.
    J Med Virol. 2024;96:e70098.
    PubMed         Abstract available
12. MAIMAITI M, Kong L, Yu Q, Wang Z, et al
    Analytical Performance of a Novel Nanopore Sequencing for SARS-CoV-2 Genomic Surveillance.
    J Med Virol. 2024;96:e70108.
    PubMed         Abstract available

    J Virol

13. ZUO F, Cao Y, Sun R, Wang Q, et al
    Ultrapotent IgA dimeric antibodies neutralize emerging Omicron variants.
    J Virol. 2024 Dec 4:e0174024. doi: 10.1128/jvi.01740.
    PubMed        
14. ZHANG Y, Zhang N, Zhang Y, Li Y, et al
    Potassium molybdate blocks APN-dependent coronavirus entry by degrading receptor via PIK3C3-mediated autophagy.
    J Virol. 2024 Dec 6:e0144924. doi: 10.1128/jvi.01449.
    PubMed         Abstract available

    JAMA

15. ANDERER S
    CDC Recommends Second COVID-19 Vaccine Dose for Older Adults.
    JAMA. 2024 Dec 6. doi: 10.1001/jama.2024.24258.
    PubMed        

    Nature

16. KUDIABOR H
    Virtual lab powered by ‘AI scientists’ super-charges biomedical research.
    Nature. 2024 Dec 4. doi: 10.1038/d41586-024-01684.
    PubMed        

    Science

17. KAISER J
    Trump picks an ‘outsider’ and NIH critic to lead agency.
    Science. 2024;386:1080-1081.
    PubMed         Abstract available

#betacoronavirus #covid #COVID19 #health #mentalHealth #research #sarbecovirus #sarsCov2 #science

#Coronavirus Disease Research #References (by AMEDEO, December 1 ’24)

1. MCGOVERN-GOOCH KR, Mani N, Gotchev D, Ardzinski A, et al
   Biological characterization of AB-343, a novel and potent SARS-CoV-2 M(pro) inhibitor with pan-coronavirus activity.
   Antiviral Res. 2024;232:106038.
   PubMed         Abstract available
2. AMIN MR, Anwar KN, Ashraf MJ, Ghassemi M, et al
   Preventing human influenza and coronaviral mono or coinfection by blocking virus-induced sialylation.
   Antiviral Res. 2024;232:106041.
   PubMed         Abstract available
3. GENG X, Zhu Y, Gao Y, Chong H, et al
   Development of lipopeptide-based HIV-1/2 fusion inhibitors targeting the gp41 pocket site with a new design strategy.
   Antiviral Res. 2024 Nov 23:106042. doi: 10.1016/j.antiviral.2024.106042.
   PubMed         Abstract available

   BMJ

4. ZERAATKAR D, Ling M, Kirsh S, Jassal T, et al
   Interventions for the management of long covid (post-covid condition): living systematic review.
   BMJ. 2024;387:e081318.
   PubMed         Abstract available

   Clin Infect Dis

5. TOWNSEND JP, Hassler HB, Dornburg A
   Optimal Annual COVID-19 Vaccine Boosting Dates Following Previous Booster Vaccination or Breakthrough Infection.
   Clin Infect Dis. 2024 Nov 26:ciae559. doi: 10.1093.
   PubMed         Abstract available
6. FAUCI AS, Folkers GK
   HIV/AIDS and COVID-19: Shared Lessons from Two Pandemics.
   Clin Infect Dis. 2024 Nov 27:ciae585. doi: 10.1093.
   PubMed         Abstract available
7. LEWIS NM, Harker EJ, Grant LB, Zhu Y, et al
   Benefit of early oseltamivir therapy for adults hospitalized with influenza A: an observational study.
   Clin Infect Dis. 2024 Nov 28:ciae584. doi: 10.1093.
   PubMed         Abstract available

   Infect Control Hosp Epidemiol

8. SANDS KE, Blanchard EJ, Hasse A, Korwek K, et al
   Risk factors for healthcare-associated infection among patients hospitalized with COVID-19 infection.
   Infect Control Hosp Epidemiol. 2024 Nov 25:1-2. doi: 10.1017/ice.2024.
   PubMed        

   Int J Infect Dis

9. CHUN HM, Osawe S, Adams-Dabban S, Favaloro J, et al
   SARS-CoV-2 Serologic Surveillance Among People Living with HIV in Nigeria, April 2022-January 2023.
   Int J Infect Dis. 2024 Nov 21:107309. doi: 10.1016/j.ijid.2024.107309.
   PubMed         Abstract available
10. YANG X, Zhang J, Liu Z, Chen S, et al
    Real-world effectiveness of COVID-19 vaccine in people with HIV compared with a matched HIV-negative cohort: a test-negative design.
    Int J Infect Dis. 2024 Nov 22:107310. doi: 10.1016/j.ijid.2024.107310.
    PubMed         Abstract available
11. PETT SL
    Predictors of hospitalisation, death and incomplete/non-recovery from SARS-CoV-2 in an ambulatory global population.
    Int J Infect Dis. 2024 Nov 26:107285. doi: 10.1016/j.ijid.2024.107285.
    PubMed         Abstract available

    J Infect

12. JIA T, Wang F, Chen Y, Liao G, et al
    Expanded immune imprinting and neutralization spectrum by hybrid immunization following breakthrough infections with SARS-CoV-2 variants after three-dose vaccination.
    J Infect. 2024 Nov 26:106362. doi: 10.1016/j.jinf.2024.106362.
    PubMed         Abstract available

    J Med Virol

13. SIDDIQUE AI, Sarmah N, Bali NK, Nausch N, et al
    Differential Gene Expression and Transcriptomics Reveal High M-Gene Expression in JN.1 and KP.1/2 Omicron Sub-Variants of SARS-CoV-2: Implications for Developing More Sensitive Diagnostic Tests.
    J Med Virol. 2024;96:e70074.
    PubMed         Abstract available
14. USHIJIMA H, Pham NTK, Nishimura S, Kobayashi M, et al
    Human Astrovirus Infection and Outbreaks in Japanese Children Before and After the Emergence of COVID-19 Pandemic.
    J Med Virol. 2024;96:e70078.
    PubMed         Abstract available
15. CHEN J, Zhang Y, Zhang B, Wang Z, et al
    In Vitro Characterization of Inhibition Function of Calcifediol to the Protease Activity of SARS-COV-2 PLpro.
    J Med Virol. 2024;96:e70085.
    PubMed         Abstract available
16. TIAN W, Han Z, Shi D, Wang H, et al
    Indeterminate Result of Interferon-gamma Release Assay-A Risk Factor of Mortality for COVID-19 and Non-COVID-19 Respiratory Infections.
    J Med Virol. 2024;96:e70058.
    PubMed         Abstract available
17. GRANINGER M, Endmayr V, Kuhner LM, Berger SM, et al
    Association Between NK Cell Genetic Variants and the Development of Long COVID Associated- and Prepandemic Small Fiber Neuropathy.
    J Med Virol. 2024;96:e70091.
    PubMed         Abstract available
18. WANG J, Ni S, Chen Q, Wang C, et al
    Discovery of a Novel Public Antibody Lineage Correlated With Inactivated SARS-CoV-2 Vaccine and the Resultant Neutralization Activity.
    J Med Virol. 2024;96:e70073.
    PubMed         Abstract available

    J Virol

19. KAKIZAKI M, Hashimoto R, Nagata N, Yamamoto T, et al
    The respective roles of TMPRSS2 and cathepsins for SARS-CoV-2 infection in human respiratory organoids.
    J Virol. 2024 Nov 27:e0185324. doi: 10.1128/jvi.01853.
    PubMed         Abstract available

    Lancet

20. FERRANTE M, D’Haens G, Jairath V, Danese S, et al
    Efficacy and safety of mirikizumab in patients with moderately-to-severely active Crohn’s disease: a phase 3, multicentre, randomised, double-blind, placebo-controlled and active-controlled, treat-through study.
    Lancet. 2024 Nov 21:S0140-6736(24)01762-8. doi: 10.1016/S0140-6736(24)01762.
    PubMed         Abstract available
21. DWYER-LINDGREN L, Baumann MM, Li Z, Kelly YO, et al
    Ten Americas: a systematic analysis of life expectancy disparities in the USA.
    Lancet. 2024 Nov 19:S0140-6736(24)01495-8. doi: 10.1016/S0140-6736(24)01495.
    PubMed         Abstract available

    Lancet Infect Dis

22. GOSWAMI J, Cardona JF, Hsu DC, Simorellis AK, et al
    Safety and immunogenicity of mRNA-1345 RSV vaccine coadministered with an influenza or COVID-19 vaccine in adults aged 50 years or older: an observer-blinded, placebo-controlled, randomised, phase 3 trial.
    Lancet Infect Dis. 2024 Nov 25:S1473-3099(24)00589.
    PubMed         Abstract available
23. LIU J, Yu Y, Jian F, Yang S, et al
    Enhanced immune evasion of SARS-CoV-2 variants KP.3.1.1 and XEC through N-terminal domain mutations.
    Lancet Infect Dis. 2024 Nov 22:S1473-3099(24)00738.
    PubMed        

    Science

24. LIBBY P
    Endothelial inflammation in COVID-19.
    Science. 2024;386:972-973.
    PubMed         Abstract available
25. COHEN J
    Children are left behind in Congo’s mpox vaccination drive.
    Science. 2024;386:954.
    PubMed         Abstract available

    Travel Med Infect Dis

26. KHAN AA, Balkhi BS, Alamri FA, Alsaleh GS, et al
    Vaccinations for Hajj: Enhancing health and global health security.
    Travel Med Infect Dis. 2024;63:102784.
    PubMed         Abstract available
27. WANG J, Ge L, Zhou K, Jiang Y, et al
    Effect of omicron infection on maternal and neonatal delivery outcomes: A retrospective cohort study.
    Travel Med Infect Dis. 2024;62:102759.
    PubMed         Abstract available

#abstract #betacoronavirus #covid #COVID19 #health #research #sarbecovirus #sarsCov2 #vaccine

#Coronavirus Disease Research #References (by AMEDEO, December 1 ’24)

1. MCGOVERN-GOOCH KR, Mani N, Gotchev D, Ardzinski A, et al
   Biological characterization of AB-343, a novel and potent SARS-CoV-2 M(pro) inhibitor with pan-coronavirus activity.
   Antiviral Res. 2024;232:106038.
   PubMed         Abstract available
2. AMIN MR, Anwar KN, Ashraf MJ, Ghassemi M, et al
   Preventing human influenza and coronaviral mono or coinfection by blocking virus-induced sialylation.
   Antiviral Res. 2024;232:106041.
   PubMed         Abstract available
3. GENG X, Zhu Y, Gao Y, Chong H, et al
   Development of lipopeptide-based HIV-1/2 fusion inhibitors targeting the gp41 pocket site with a new design strategy.
   Antiviral Res. 2024 Nov 23:106042. doi: 10.1016/j.antiviral.2024.106042.
   PubMed         Abstract available

   BMJ

4. ZERAATKAR D, Ling M, Kirsh S, Jassal T, et al
   Interventions for the management of long covid (post-covid condition): living systematic review.
   BMJ. 2024;387:e081318.
   PubMed         Abstract available

   Clin Infect Dis

5. TOWNSEND JP, Hassler HB, Dornburg A
   Optimal Annual COVID-19 Vaccine Boosting Dates Following Previous Booster Vaccination or Breakthrough Infection.
   Clin Infect Dis. 2024 Nov 26:ciae559. doi: 10.1093.
   PubMed         Abstract available
6. FAUCI AS, Folkers GK
   HIV/AIDS and COVID-19: Shared Lessons from Two Pandemics.
   Clin Infect Dis. 2024 Nov 27:ciae585. doi: 10.1093.
   PubMed         Abstract available
7. LEWIS NM, Harker EJ, Grant LB, Zhu Y, et al
   Benefit of early oseltamivir therapy for adults hospitalized with influenza A: an observational study.
   Clin Infect Dis. 2024 Nov 28:ciae584. doi: 10.1093.
   PubMed         Abstract available

   Infect Control Hosp Epidemiol

8. SANDS KE, Blanchard EJ, Hasse A, Korwek K, et al
   Risk factors for healthcare-associated infection among patients hospitalized with COVID-19 infection.
   Infect Control Hosp Epidemiol. 2024 Nov 25:1-2. doi: 10.1017/ice.2024.
   PubMed        

   Int J Infect Dis

9. CHUN HM, Osawe S, Adams-Dabban S, Favaloro J, et al
   SARS-CoV-2 Serologic Surveillance Among People Living with HIV in Nigeria, April 2022-January 2023.
   Int J Infect Dis. 2024 Nov 21:107309. doi: 10.1016/j.ijid.2024.107309.
   PubMed         Abstract available
10. YANG X, Zhang J, Liu Z, Chen S, et al
    Real-world effectiveness of COVID-19 vaccine in people with HIV compared with a matched HIV-negative cohort: a test-negative design.
    Int J Infect Dis. 2024 Nov 22:107310. doi: 10.1016/j.ijid.2024.107310.
    PubMed         Abstract available
11. PETT SL
    Predictors of hospitalisation, death and incomplete/non-recovery from SARS-CoV-2 in an ambulatory global population.
    Int J Infect Dis. 2024 Nov 26:107285. doi: 10.1016/j.ijid.2024.107285.
    PubMed         Abstract available

    J Infect

12. JIA T, Wang F, Chen Y, Liao G, et al
    Expanded immune imprinting and neutralization spectrum by hybrid immunization following breakthrough infections with SARS-CoV-2 variants after three-dose vaccination.
    J Infect. 2024 Nov 26:106362. doi: 10.1016/j.jinf.2024.106362.
    PubMed         Abstract available

    J Med Virol

13. SIDDIQUE AI, Sarmah N, Bali NK, Nausch N, et al
    Differential Gene Expression and Transcriptomics Reveal High M-Gene Expression in JN.1 and KP.1/2 Omicron Sub-Variants of SARS-CoV-2: Implications for Developing More Sensitive Diagnostic Tests.
    J Med Virol. 2024;96:e70074.
    PubMed         Abstract available
14. USHIJIMA H, Pham NTK, Nishimura S, Kobayashi M, et al
    Human Astrovirus Infection and Outbreaks in Japanese Children Before and After the Emergence of COVID-19 Pandemic.
    J Med Virol. 2024;96:e70078.
    PubMed         Abstract available
15. CHEN J, Zhang Y, Zhang B, Wang Z, et al
    In Vitro Characterization of Inhibition Function of Calcifediol to the Protease Activity of SARS-COV-2 PLpro.
    J Med Virol. 2024;96:e70085.
    PubMed         Abstract available
16. TIAN W, Han Z, Shi D, Wang H, et al
    Indeterminate Result of Interferon-gamma Release Assay-A Risk Factor of Mortality for COVID-19 and Non-COVID-19 Respiratory Infections.
    J Med Virol. 2024;96:e70058.
    PubMed         Abstract available
17. GRANINGER M, Endmayr V, Kuhner LM, Berger SM, et al
    Association Between NK Cell Genetic Variants and the Development of Long COVID Associated- and Prepandemic Small Fiber Neuropathy.
    J Med Virol. 2024;96:e70091.
    PubMed         Abstract available
18. WANG J, Ni S, Chen Q, Wang C, et al
    Discovery of a Novel Public Antibody Lineage Correlated With Inactivated SARS-CoV-2 Vaccine and the Resultant Neutralization Activity.
    J Med Virol. 2024;96:e70073.
    PubMed         Abstract available

    J Virol

19. KAKIZAKI M, Hashimoto R, Nagata N, Yamamoto T, et al
    The respective roles of TMPRSS2 and cathepsins for SARS-CoV-2 infection in human respiratory organoids.
    J Virol. 2024 Nov 27:e0185324. doi: 10.1128/jvi.01853.
    PubMed         Abstract available

    Lancet

20. FERRANTE M, D’Haens G, Jairath V, Danese S, et al
    Efficacy and safety of mirikizumab in patients with moderately-to-severely active Crohn’s disease: a phase 3, multicentre, randomised, double-blind, placebo-controlled and active-controlled, treat-through study.
    Lancet. 2024 Nov 21:S0140-6736(24)01762-8. doi: 10.1016/S0140-6736(24)01762.
    PubMed         Abstract available
21. DWYER-LINDGREN L, Baumann MM, Li Z, Kelly YO, et al
    Ten Americas: a systematic analysis of life expectancy disparities in the USA.
    Lancet. 2024 Nov 19:S0140-6736(24)01495-8. doi: 10.1016/S0140-6736(24)01495.
    PubMed         Abstract available

    Lancet Infect Dis

22. GOSWAMI J, Cardona JF, Hsu DC, Simorellis AK, et al
    Safety and immunogenicity of mRNA-1345 RSV vaccine coadministered with an influenza or COVID-19 vaccine in adults aged 50 years or older: an observer-blinded, placebo-controlled, randomised, phase 3 trial.
    Lancet Infect Dis. 2024 Nov 25:S1473-3099(24)00589.
    PubMed         Abstract available
23. LIU J, Yu Y, Jian F, Yang S, et al
    Enhanced immune evasion of SARS-CoV-2 variants KP.3.1.1 and XEC through N-terminal domain mutations.
    Lancet Infect Dis. 2024 Nov 22:S1473-3099(24)00738.
    PubMed        

    Science

24. LIBBY P
    Endothelial inflammation in COVID-19.
    Science. 2024;386:972-973.
    PubMed         Abstract available
25. COHEN J
    Children are left behind in Congo’s mpox vaccination drive.
    Science. 2024;386:954.
    PubMed         Abstract available

    Travel Med Infect Dis

26. KHAN AA, Balkhi BS, Alamri FA, Alsaleh GS, et al
    Vaccinations for Hajj: Enhancing health and global health security.
    Travel Med Infect Dis. 2024;63:102784.
    PubMed         Abstract available
27. WANG J, Ge L, Zhou K, Jiang Y, et al
    Effect of omicron infection on maternal and neonatal delivery outcomes: A retrospective cohort study.
    Travel Med Infect Dis. 2024;62:102759.
    PubMed         Abstract available

#abstract #betacoronavirus #covid #COVID19 #health #research #sarbecovirus #sarsCov2 #vaccine

#Coronavirus Disease Research #References (by AMEDEO, December 1 ’24)

1. MCGOVERN-GOOCH KR, Mani N, Gotchev D, Ardzinski A, et al
   Biological characterization of AB-343, a novel and potent SARS-CoV-2 M(pro) inhibitor with pan-coronavirus activity.
   Antiviral Res. 2024;232:106038.
   PubMed         Abstract available
2. AMIN MR, Anwar KN, Ashraf MJ, Ghassemi M, et al
   Preventing human influenza and coronaviral mono or coinfection by blocking virus-induced sialylation.
   Antiviral Res. 2024;232:106041.
   PubMed         Abstract available
3. GENG X, Zhu Y, Gao Y, Chong H, et al
   Development of lipopeptide-based HIV-1/2 fusion inhibitors targeting the gp41 pocket site with a new design strategy.
   Antiviral Res. 2024 Nov 23:106042. doi: 10.1016/j.antiviral.2024.106042.
   PubMed         Abstract available

   BMJ

4. ZERAATKAR D, Ling M, Kirsh S, Jassal T, et al
   Interventions for the management of long covid (post-covid condition): living systematic review.
   BMJ. 2024;387:e081318.
   PubMed         Abstract available

   Clin Infect Dis

5. TOWNSEND JP, Hassler HB, Dornburg A
   Optimal Annual COVID-19 Vaccine Boosting Dates Following Previous Booster Vaccination or Breakthrough Infection.
   Clin Infect Dis. 2024 Nov 26:ciae559. doi: 10.1093.
   PubMed         Abstract available
6. FAUCI AS, Folkers GK
   HIV/AIDS and COVID-19: Shared Lessons from Two Pandemics.
   Clin Infect Dis. 2024 Nov 27:ciae585. doi: 10.1093.
   PubMed         Abstract available
7. LEWIS NM, Harker EJ, Grant LB, Zhu Y, et al
   Benefit of early oseltamivir therapy for adults hospitalized with influenza A: an observational study.
   Clin Infect Dis. 2024 Nov 28:ciae584. doi: 10.1093.
   PubMed         Abstract available

   Infect Control Hosp Epidemiol

8. SANDS KE, Blanchard EJ, Hasse A, Korwek K, et al
   Risk factors for healthcare-associated infection among patients hospitalized with COVID-19 infection.
   Infect Control Hosp Epidemiol. 2024 Nov 25:1-2. doi: 10.1017/ice.2024.
   PubMed        

   Int J Infect Dis

9. CHUN HM, Osawe S, Adams-Dabban S, Favaloro J, et al
   SARS-CoV-2 Serologic Surveillance Among People Living with HIV in Nigeria, April 2022-January 2023.
   Int J Infect Dis. 2024 Nov 21:107309. doi: 10.1016/j.ijid.2024.107309.
   PubMed         Abstract available
10. YANG X, Zhang J, Liu Z, Chen S, et al
    Real-world effectiveness of COVID-19 vaccine in people with HIV compared with a matched HIV-negative cohort: a test-negative design.
    Int J Infect Dis. 2024 Nov 22:107310. doi: 10.1016/j.ijid.2024.107310.
    PubMed         Abstract available
11. PETT SL
    Predictors of hospitalisation, death and incomplete/non-recovery from SARS-CoV-2 in an ambulatory global population.
    Int J Infect Dis. 2024 Nov 26:107285. doi: 10.1016/j.ijid.2024.107285.
    PubMed         Abstract available

    J Infect

12. JIA T, Wang F, Chen Y, Liao G, et al
    Expanded immune imprinting and neutralization spectrum by hybrid immunization following breakthrough infections with SARS-CoV-2 variants after three-dose vaccination.
    J Infect. 2024 Nov 26:106362. doi: 10.1016/j.jinf.2024.106362.
    PubMed         Abstract available

    J Med Virol

13. SIDDIQUE AI, Sarmah N, Bali NK, Nausch N, et al
    Differential Gene Expression and Transcriptomics Reveal High M-Gene Expression in JN.1 and KP.1/2 Omicron Sub-Variants of SARS-CoV-2: Implications for Developing More Sensitive Diagnostic Tests.
    J Med Virol. 2024;96:e70074.
    PubMed         Abstract available
14. USHIJIMA H, Pham NTK, Nishimura S, Kobayashi M, et al
    Human Astrovirus Infection and Outbreaks in Japanese Children Before and After the Emergence of COVID-19 Pandemic.
    J Med Virol. 2024;96:e70078.
    PubMed         Abstract available
15. CHEN J, Zhang Y, Zhang B, Wang Z, et al
    In Vitro Characterization of Inhibition Function of Calcifediol to the Protease Activity of SARS-COV-2 PLpro.
    J Med Virol. 2024;96:e70085.
    PubMed         Abstract available
16. TIAN W, Han Z, Shi D, Wang H, et al
    Indeterminate Result of Interferon-gamma Release Assay-A Risk Factor of Mortality for COVID-19 and Non-COVID-19 Respiratory Infections.
    J Med Virol. 2024;96:e70058.
    PubMed         Abstract available
17. GRANINGER M, Endmayr V, Kuhner LM, Berger SM, et al
    Association Between NK Cell Genetic Variants and the Development of Long COVID Associated- and Prepandemic Small Fiber Neuropathy.
    J Med Virol. 2024;96:e70091.
    PubMed         Abstract available
18. WANG J, Ni S, Chen Q, Wang C, et al
    Discovery of a Novel Public Antibody Lineage Correlated With Inactivated SARS-CoV-2 Vaccine and the Resultant Neutralization Activity.
    J Med Virol. 2024;96:e70073.
    PubMed         Abstract available

    J Virol

19. KAKIZAKI M, Hashimoto R, Nagata N, Yamamoto T, et al
    The respective roles of TMPRSS2 and cathepsins for SARS-CoV-2 infection in human respiratory organoids.
    J Virol. 2024 Nov 27:e0185324. doi: 10.1128/jvi.01853.
    PubMed         Abstract available

    Lancet

20. FERRANTE M, D’Haens G, Jairath V, Danese S, et al
    Efficacy and safety of mirikizumab in patients with moderately-to-severely active Crohn’s disease: a phase 3, multicentre, randomised, double-blind, placebo-controlled and active-controlled, treat-through study.
    Lancet. 2024 Nov 21:S0140-6736(24)01762-8. doi: 10.1016/S0140-6736(24)01762.
    PubMed         Abstract available
21. DWYER-LINDGREN L, Baumann MM, Li Z, Kelly YO, et al
    Ten Americas: a systematic analysis of life expectancy disparities in the USA.
    Lancet. 2024 Nov 19:S0140-6736(24)01495-8. doi: 10.1016/S0140-6736(24)01495.
    PubMed         Abstract available

    Lancet Infect Dis

22. GOSWAMI J, Cardona JF, Hsu DC, Simorellis AK, et al
    Safety and immunogenicity of mRNA-1345 RSV vaccine coadministered with an influenza or COVID-19 vaccine in adults aged 50 years or older: an observer-blinded, placebo-controlled, randomised, phase 3 trial.
    Lancet Infect Dis. 2024 Nov 25:S1473-3099(24)00589.
    PubMed         Abstract available
23. LIU J, Yu Y, Jian F, Yang S, et al
    Enhanced immune evasion of SARS-CoV-2 variants KP.3.1.1 and XEC through N-terminal domain mutations.
    Lancet Infect Dis. 2024 Nov 22:S1473-3099(24)00738.
    PubMed        

    Science

24. LIBBY P
    Endothelial inflammation in COVID-19.
    Science. 2024;386:972-973.
    PubMed         Abstract available
25. COHEN J
    Children are left behind in Congo’s mpox vaccination drive.
    Science. 2024;386:954.
    PubMed         Abstract available

    Travel Med Infect Dis

26. KHAN AA, Balkhi BS, Alamri FA, Alsaleh GS, et al
    Vaccinations for Hajj: Enhancing health and global health security.
    Travel Med Infect Dis. 2024;63:102784.
    PubMed         Abstract available
27. WANG J, Ge L, Zhou K, Jiang Y, et al
    Effect of omicron infection on maternal and neonatal delivery outcomes: A retrospective cohort study.
    Travel Med Infect Dis. 2024;62:102759.
    PubMed         Abstract available

#abstract #betacoronavirus #covid #COVID19 #health #research #sarbecovirus #sarsCov2 #vaccine

#Coronavirus Disease Research #References (by AMEDEO, December 1 ’24)

1. MCGOVERN-GOOCH KR, Mani N, Gotchev D, Ardzinski A, et al
   Biological characterization of AB-343, a novel and potent SARS-CoV-2 M(pro) inhibitor with pan-coronavirus activity.
   Antiviral Res. 2024;232:106038.
   PubMed         Abstract available
2. AMIN MR, Anwar KN, Ashraf MJ, Ghassemi M, et al
   Preventing human influenza and coronaviral mono or coinfection by blocking virus-induced sialylation.
   Antiviral Res. 2024;232:106041.
   PubMed         Abstract available
3. GENG X, Zhu Y, Gao Y, Chong H, et al
   Development of lipopeptide-based HIV-1/2 fusion inhibitors targeting the gp41 pocket site with a new design strategy.
   Antiviral Res. 2024 Nov 23:106042. doi: 10.1016/j.antiviral.2024.106042.
   PubMed         Abstract available

   BMJ

4. ZERAATKAR D, Ling M, Kirsh S, Jassal T, et al
   Interventions for the management of long covid (post-covid condition): living systematic review.
   BMJ. 2024;387:e081318.
   PubMed         Abstract available

   Clin Infect Dis

5. TOWNSEND JP, Hassler HB, Dornburg A
   Optimal Annual COVID-19 Vaccine Boosting Dates Following Previous Booster Vaccination or Breakthrough Infection.
   Clin Infect Dis. 2024 Nov 26:ciae559. doi: 10.1093.
   PubMed         Abstract available
6. FAUCI AS, Folkers GK
   HIV/AIDS and COVID-19: Shared Lessons from Two Pandemics.
   Clin Infect Dis. 2024 Nov 27:ciae585. doi: 10.1093.
   PubMed         Abstract available
7. LEWIS NM, Harker EJ, Grant LB, Zhu Y, et al
   Benefit of early oseltamivir therapy for adults hospitalized with influenza A: an observational study.
   Clin Infect Dis. 2024 Nov 28:ciae584. doi: 10.1093.
   PubMed         Abstract available

   Infect Control Hosp Epidemiol

8. SANDS KE, Blanchard EJ, Hasse A, Korwek K, et al
   Risk factors for healthcare-associated infection among patients hospitalized with COVID-19 infection.
   Infect Control Hosp Epidemiol. 2024 Nov 25:1-2. doi: 10.1017/ice.2024.
   PubMed        

   Int J Infect Dis

9. CHUN HM, Osawe S, Adams-Dabban S, Favaloro J, et al
   SARS-CoV-2 Serologic Surveillance Among People Living with HIV in Nigeria, April 2022-January 2023.
   Int J Infect Dis. 2024 Nov 21:107309. doi: 10.1016/j.ijid.2024.107309.
   PubMed         Abstract available
10. YANG X, Zhang J, Liu Z, Chen S, et al
    Real-world effectiveness of COVID-19 vaccine in people with HIV compared with a matched HIV-negative cohort: a test-negative design.
    Int J Infect Dis. 2024 Nov 22:107310. doi: 10.1016/j.ijid.2024.107310.
    PubMed         Abstract available
11. PETT SL
    Predictors of hospitalisation, death and incomplete/non-recovery from SARS-CoV-2 in an ambulatory global population.
    Int J Infect Dis. 2024 Nov 26:107285. doi: 10.1016/j.ijid.2024.107285.
    PubMed         Abstract available

    J Infect

12. JIA T, Wang F, Chen Y, Liao G, et al
    Expanded immune imprinting and neutralization spectrum by hybrid immunization following breakthrough infections with SARS-CoV-2 variants after three-dose vaccination.
    J Infect. 2024 Nov 26:106362. doi: 10.1016/j.jinf.2024.106362.
    PubMed         Abstract available

    J Med Virol

13. SIDDIQUE AI, Sarmah N, Bali NK, Nausch N, et al
    Differential Gene Expression and Transcriptomics Reveal High M-Gene Expression in JN.1 and KP.1/2 Omicron Sub-Variants of SARS-CoV-2: Implications for Developing More Sensitive Diagnostic Tests.
    J Med Virol. 2024;96:e70074.
    PubMed         Abstract available
14. USHIJIMA H, Pham NTK, Nishimura S, Kobayashi M, et al
    Human Astrovirus Infection and Outbreaks in Japanese Children Before and After the Emergence of COVID-19 Pandemic.
    J Med Virol. 2024;96:e70078.
    PubMed         Abstract available
15. CHEN J, Zhang Y, Zhang B, Wang Z, et al
    In Vitro Characterization of Inhibition Function of Calcifediol to the Protease Activity of SARS-COV-2 PLpro.
    J Med Virol. 2024;96:e70085.
    PubMed         Abstract available
16. TIAN W, Han Z, Shi D, Wang H, et al
    Indeterminate Result of Interferon-gamma Release Assay-A Risk Factor of Mortality for COVID-19 and Non-COVID-19 Respiratory Infections.
    J Med Virol. 2024;96:e70058.
    PubMed         Abstract available
17. GRANINGER M, Endmayr V, Kuhner LM, Berger SM, et al
    Association Between NK Cell Genetic Variants and the Development of Long COVID Associated- and Prepandemic Small Fiber Neuropathy.
    J Med Virol. 2024;96:e70091.
    PubMed         Abstract available
18. WANG J, Ni S, Chen Q, Wang C, et al
    Discovery of a Novel Public Antibody Lineage Correlated With Inactivated SARS-CoV-2 Vaccine and the Resultant Neutralization Activity.
    J Med Virol. 2024;96:e70073.
    PubMed         Abstract available

    J Virol

19. KAKIZAKI M, Hashimoto R, Nagata N, Yamamoto T, et al
    The respective roles of TMPRSS2 and cathepsins for SARS-CoV-2 infection in human respiratory organoids.
    J Virol. 2024 Nov 27:e0185324. doi: 10.1128/jvi.01853.
    PubMed         Abstract available

    Lancet

20. FERRANTE M, D’Haens G, Jairath V, Danese S, et al
    Efficacy and safety of mirikizumab in patients with moderately-to-severely active Crohn’s disease: a phase 3, multicentre, randomised, double-blind, placebo-controlled and active-controlled, treat-through study.
    Lancet. 2024 Nov 21:S0140-6736(24)01762-8. doi: 10.1016/S0140-6736(24)01762.
    PubMed         Abstract available
21. DWYER-LINDGREN L, Baumann MM, Li Z, Kelly YO, et al
    Ten Americas: a systematic analysis of life expectancy disparities in the USA.
    Lancet. 2024 Nov 19:S0140-6736(24)01495-8. doi: 10.1016/S0140-6736(24)01495.
    PubMed         Abstract available

    Lancet Infect Dis

22. GOSWAMI J, Cardona JF, Hsu DC, Simorellis AK, et al
    Safety and immunogenicity of mRNA-1345 RSV vaccine coadministered with an influenza or COVID-19 vaccine in adults aged 50 years or older: an observer-blinded, placebo-controlled, randomised, phase 3 trial.
    Lancet Infect Dis. 2024 Nov 25:S1473-3099(24)00589.
    PubMed         Abstract available
23. LIU J, Yu Y, Jian F, Yang S, et al
    Enhanced immune evasion of SARS-CoV-2 variants KP.3.1.1 and XEC through N-terminal domain mutations.
    Lancet Infect Dis. 2024 Nov 22:S1473-3099(24)00738.
    PubMed        

    Science

24. LIBBY P
    Endothelial inflammation in COVID-19.
    Science. 2024;386:972-973.
    PubMed         Abstract available
25. COHEN J
    Children are left behind in Congo’s mpox vaccination drive.
    Science. 2024;386:954.
    PubMed         Abstract available

    Travel Med Infect Dis

26. KHAN AA, Balkhi BS, Alamri FA, Alsaleh GS, et al
    Vaccinations for Hajj: Enhancing health and global health security.
    Travel Med Infect Dis. 2024;63:102784.
    PubMed         Abstract available
27. WANG J, Ge L, Zhou K, Jiang Y, et al
    Effect of omicron infection on maternal and neonatal delivery outcomes: A retrospective cohort study.
    Travel Med Infect Dis. 2024;62:102759.
    PubMed         Abstract available

#abstract #betacoronavirus #covid #COVID19 #health #research #sarbecovirus #sarsCov2 #vaccine

#Recombination across distant #coronavirid #species and #genera is a rare #event with distinct #genomic features

Source: Journal of Virology, https://journals.asm.org/doi/full/10.1128/jvi.01100-24?af=R

ABSTRACT
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2; family Coronaviridae, genus Betacoronavirus, subgenus Sarbecovirus) has caused millions of deaths, prompting a need for better understanding of coronavirid emergence and spillover to humans. As an evaluation of how some features of SARS-CoV-2, unique among sarbecoviruses, may have been acquired from related viruses, we conducted phylogenetic and recombination analyses to compare the frequency of recombination among coronavirids across vs within genera, subgenera, and species. Among known betacoronaviruses, we identified 199 (183 intraspecies, 16 interspecies, but no intersubgenera) recombination events. Phylogenetic analyses revealed that the ancestry of interspecies events was limited and less prone to affect 5′ regions of coronavirid genome open reading frame 1 (ORF1) than intraspecies events. On the contrary, interspecies events were significantly more prone to impact the 3′ end (ORF6–ORF8 and the nucleocapsid protein [N] ORF), suggesting the existence of region-specific constraints on recombination. This work substantiated that recombination among betacoronaviruses is limited by the genome similarity between their parental viruses. We conclude that SARS-CoV-2 likely acquired unique features through recombination with closely related circulating sarbecoviruses (most likely from the same species) that co-existed geographically.

____

#abstract #betacoronavirus #biology #coronavirus #evolution #genetics #health #research #sarbecovirus #sarsCov2 #science

#Recombination across distant #coronavirid #species and #genera is a rare #event with distinct #genomic features

Source: Journal of Virology, https://journals.asm.org/doi/full/10.1128/jvi.01100-24?af=R

ABSTRACT
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2; family Coronaviridae, genus Betacoronavirus, subgenus Sarbecovirus) has caused millions of deaths, prompting a need for better understanding of coronavirid emergence and spillover to humans. As an evaluation of how some features of SARS-CoV-2, unique among sarbecoviruses, may have been acquired from related viruses, we conducted phylogenetic and recombination analyses to compare the frequency of recombination among coronavirids across vs within genera, subgenera, and species. Among known betacoronaviruses, we identified 199 (183 intraspecies, 16 interspecies, but no intersubgenera) recombination events. Phylogenetic analyses revealed that the ancestry of interspecies events was limited and less prone to affect 5′ regions of coronavirid genome open reading frame 1 (ORF1) than intraspecies events. On the contrary, interspecies events were significantly more prone to impact the 3′ end (ORF6–ORF8 and the nucleocapsid protein [N] ORF), suggesting the existence of region-specific constraints on recombination. This work substantiated that recombination among betacoronaviruses is limited by the genome similarity between their parental viruses. We conclude that SARS-CoV-2 likely acquired unique features through recombination with closely related circulating sarbecoviruses (most likely from the same species) that co-existed geographically.

____

#abstract #betacoronavirus #biology #coronavirus #evolution #genetics #health #research #sarbecovirus #sarsCov2 #science

#Recombination across distant #coronavirid #species and #genera is a rare #event with distinct #genomic features

Source: Journal of Virology, https://journals.asm.org/doi/full/10.1128/jvi.01100-24?af=R

ABSTRACT
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2; family Coronaviridae, genus Betacoronavirus, subgenus Sarbecovirus) has caused millions of deaths, prompting a need for better understanding of coronavirid emergence and spillover to humans. As an evaluation of how some features of SARS-CoV-2, unique among sarbecoviruses, may have been acquired from related viruses, we conducted phylogenetic and recombination analyses to compare the frequency of recombination among coronavirids across vs within genera, subgenera, and species. Among known betacoronaviruses, we identified 199 (183 intraspecies, 16 interspecies, but no intersubgenera) recombination events. Phylogenetic analyses revealed that the ancestry of interspecies events was limited and less prone to affect 5′ regions of coronavirid genome open reading frame 1 (ORF1) than intraspecies events. On the contrary, interspecies events were significantly more prone to impact the 3′ end (ORF6–ORF8 and the nucleocapsid protein [N] ORF), suggesting the existence of region-specific constraints on recombination. This work substantiated that recombination among betacoronaviruses is limited by the genome similarity between their parental viruses. We conclude that SARS-CoV-2 likely acquired unique features through recombination with closely related circulating sarbecoviruses (most likely from the same species) that co-existed geographically.

____

#abstract #betacoronavirus #biology #coronavirus #evolution #genetics #health #research #sarbecovirus #sarsCov2 #science

#Recombination across distant #coronavirid #species and #genera is a rare #event with distinct #genomic features

Source: Journal of Virology, https://journals.asm.org/doi/full/10.1128/jvi.01100-24?af=R

ABSTRACT
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2; family Coronaviridae, genus Betacoronavirus, subgenus Sarbecovirus) has caused millions of deaths, prompting a need for better understanding of coronavirid emergence and spillover to humans. As an evaluation of how some features of SARS-CoV-2, unique among sarbecoviruses, may have been acquired from related viruses, we conducted phylogenetic and recombination analyses to compare the frequency of recombination among coronavirids across vs within genera, subgenera, and species. Among known betacoronaviruses, we identified 199 (183 intraspecies, 16 interspecies, but no intersubgenera) recombination events. Phylogenetic analyses revealed that the ancestry of interspecies events was limited and less prone to affect 5′ regions of coronavirid genome open reading frame 1 (ORF1) than intraspecies events. On the contrary, interspecies events were significantly more prone to impact the 3′ end (ORF6–ORF8 and the nucleocapsid protein [N] ORF), suggesting the existence of region-specific constraints on recombination. This work substantiated that recombination among betacoronaviruses is limited by the genome similarity between their parental viruses. We conclude that SARS-CoV-2 likely acquired unique features through recombination with closely related circulating sarbecoviruses (most likely from the same species) that co-existed geographically.

____

#abstract #betacoronavirus #biology #coronavirus #evolution #genetics #health #research #sarbecovirus #sarsCov2 #science

#Coronavirus Disease Research #References (by AMEDEO, Nov. 16 ’24)

1. AYYALA-SOMAYAJULA D, Dodge JL, Leventhal AM, Terrault NA, et al
   Trends in Alcohol Use After the COVID-19 Pandemic: A National Cross-Sectional Study.
   Ann Intern Med. 2024 Nov 12. doi: 10.7326/ANNALS-24-02157.
   PubMed        

   Antiviral Res

2. SAMA B, Selisko B, Falcou C, Fattorini V, et al
   The effects of Remdesivir’s functional groups on its antiviral potency and resistance against the SARS-CoV-2 polymerase.
   Antiviral Res. 2024 Nov 5:106034. doi: 10.1016/j.antiviral.2024.106034.
   PubMed         Abstract available

   BMJ

3. GREENHALGH T, Misak C, Payne R, Swann N, et al
   Patient involvement in developing clinical guidelines.
   BMJ. 2024;387:q2433.
   PubMed        

   Br J Anaesth

4. ANGELOPOULOS N, Staines J, Chamberlin M, Bates S, et al
   A narrative review of personal protective equipment gowns: lessons from COVID-19.
   Br J Anaesth. 2024 Nov 7:S0007-0912(24)00567-1. doi: 10.1016/j.bja.2024.
   PubMed         Abstract available

   Clin Infect Dis

5. GRANT R, de Kraker MEA, Buetti N, Jackson H, et al
   In-hospital outcomes of healthcare-associated COVID-19 (Omicron) versus healthcare-associated influenza: a retrospective, nationwide cohort study in Switzerland.
   Clin Infect Dis. 2024 Nov 13:ciae558. doi: 10.1093.
   PubMed         Abstract available
6. HAMMOND J, Leister-Tebbe H, Gardner A, Abreu P, et al
   Alleviation of COVID-19 Symptoms and Reduction in Healthcare Utilization Among High-Risk Patients Treated With Nirmatrelvir/Ritonavir (NMV/R): A phase 3 randomized trial.
   Clin Infect Dis. 2024 Nov 11:ciae551. doi: 10.1093.
   PubMed         Abstract available

   Emerg Infect Dis

7. CREPPAGE KE, Gallaway MS, Russell DA, Early JM, et al
   Global Emerging Infections Surveillance Program Contributions to Pandemic Preparedness and Response.
   Emerg Infect Dis. 2024;30:9-12.
   PubMed         Abstract available
8. MORTON LC, Rahman N, Bishop-Lilly KA
   Next-Generation Sequencing and Bioinformatics Consortium Approach to Genomic Surveillance.
   Emerg Infect Dis. 2024;30:13-18.
   PubMed         Abstract available
9. MUEHLEMAN D, Gruner B, Hogan V, Fanning P, et al
   Using SARS-CoV-2 Sequencing Data to Identify Reinfection Cases in the Global Emerging Infections Surveillance Program, United States.
   Emerg Infect Dis. 2024;30:53-61.
   PubMed         Abstract available
10. TINOCO YO, Osman TS, Ampuero JS, Gazo M, et al
    Respiratory Disease Surveillance in the Middle East and Latin America during the COVID-19 Pandemic, 2020-2022.
    Emerg Infect Dis. 2024;30:26-32.
    PubMed         Abstract available
11. ODUNDO EA, Kipkirui EC, Koech MC, Kirui MC, et al
    Azithromycin Resistance Patterns in Escherichia coli and Shigella before and after COVID-19, Kenya.
    Emerg Infect Dis. 2024;30:86-93.
    PubMed         Abstract available

    Int J Infect Dis

12. GRIFFITHS M, Hatabah D, Sullivan P, Mantus G, et al
    Corrigendum to “Incidence of SARS-CoV-2 seropositivity in pediatric healthcare workers prior to widespread vaccination: A 5-month longitudinal cohort study” [Internation Journal of Infectious Diseases, volume 144 (2024) 107064].
    Int J Infect Dis. 2024;149:107278.
    PubMed        
13. LASTRUCCI V, Pacifici M, Puglia M, Alderotti G, et al
    Erratum to ‘Seasonality and severity of respiratory syncytial virus during the COVID-19 pandemic: a dynamic cohort study’.
    Int J Infect Dis. 2024;149:107286.
    PubMed        

    Intensive Care Med

14. KESECIOGLU J, Rusinova K, Alampi D, Arabi YM, et al
    European Society of Intensive Care Medicine guidelines on end of life and palliative care in the intensive care unit.
    Intensive Care Med. 2024 Oct 3. doi: 10.1007/s00134-024-07579.
    PubMed         Abstract available
15. OLMOS M, Esperatti M, Fuentes N, Miranda Tirado A, et al
    Early physiologic changes after awake prone positioning predict clinical outcomes in patients with acute hypoxemic respiratory failure.
    Intensive Care Med. 2024 Nov 14. doi: 10.1007/s00134-024-07690.
    PubMed         Abstract available

    J Infect

16. DULFER EA, Fohse K, Taks EJM, Moorlag SJCFM, et al
    The effect of BCG vaccination in the elderly on infectious and non-infectious immune-mediated diseases.
    J Infect. 2024;89:106344.
    PubMed         Abstract available
17. HAN B, Du C, Deng M, Tang R, et al
    Real-world effectiveness and safety of simnotrelvir/ritonavir for COVID-19: A nationwide, multicenter, prospective, observational cohort study in China.
    J Infect. 2024 Nov 7:106339. doi: 10.1016/j.jinf.2024.106339.
    PubMed         Abstract available
18. FOONG KS
    Corrigendum to “The IL-6 hypothesis in COVID-19: A phase 2, randomised, double-blind, placebo-controlled study to evaluate the efficacy and safety of free IL-6 sequestration by the monoclonal antibody sirukumab in severe and critical COVID-19” [J Infe
    J Infect. 2024;89:106343.
    PubMed        

    J Med Virol

19. USTIUZHANINA MO, Boyko AA, Vavilova JD, Siniavin AE, et al
    The Antigen-Specific Response of NK Cells to SARS-CoV-2 Correlates With KIR2DS4 Expression.
    J Med Virol. 2024;96:e70057.
    PubMed         Abstract available
20. ZHANG C, Wang M, Sun S, Yi M, et al
    Impact of COVID-19 on the Prevalence and Drug Resistance of Bacteria Isolated From Bacterial Meningitis Cerebrospinal Fluid in Shandong Province: A Multicenter Retrospective Study.
    J Med Virol. 2024;96:e70063.
    PubMed         Abstract available
21. ESPI M, Charmetant X, Benotmane I, Lefsihane K, et al
    Memory B Cells Provide Long-Term Protection to Vaccinated Kidney Transplant Recipients Against SARS-CoV-2 Variants.
    J Med Virol. 2024;96:e70037.
    PubMed         Abstract available
22. FACCO JV, Addas-Carvalho M, Duarte ADSS, Zangirolami AB, et al
    HLA-B*15 Is Associated With SARS-CoV-2 Infection in a Brazilian Population.
    J Med Virol. 2024;96:e70028.
    PubMed         Abstract available
23. WANG N, Lin Q, Fan H, Wang Y, et al
    BIC/FTC/TAF Benefits People Living With HIV After Omicron Breakthrough Infection in Shortening Duration of Symptoms, Enhancing Specific Immune Response and Increasing Total CD4 Cells.
    J Med Virol. 2024;96:e70036.
    PubMed         Abstract available
24. YE C, Tian Y, Huo D, Zhang T, et al
    Changes in Epidemics of Respiratory Viral Infections Resulted From the COVID-19 Pandemic in Shanghai.
    J Med Virol. 2024;96:e70034.
    PubMed         Abstract available

    J Virol

25. CHEN Y, Ou X, Li P, Zan F, et al
    Identification of the critical residues of TMPRSS2 for entry and host range of human coronavirus HKU1.
    J Virol. 2024 Nov 11:e0158724. doi: 10.1128/jvi.01587.
    PubMed         Abstract available
26. STEIGMANN JC, Zhou X, Suttenberg LN, Salman I, et al
    Effects of immunoproteasome inhibition on acute respiratory infection with murine hepatitis virus strain 1.
    J Virol. 2024 Nov 7:e0123824. doi: 10.1128/jvi.01238.
    PubMed         Abstract available

    JAMA

27. ANDERER S
    FDA Authorizes First At-Home COVID-19 and Flu Combo Test.
    JAMA. 2024 Nov 8. doi: 10.1001/jama.2024.22561.
    PubMed        

    Lancet

28. DWYER-LINDGREN L, Kendrick P, Baumann MM, Li Z, et al
    Disparities in wellbeing in the USA by race and ethnicity, age, sex, and location, 2008-21: an analysis using the Human Development Index.
    Lancet. 2024 Nov 6:S0140-6736(24)01757-4. doi: 10.1016/S0140-6736(24)01757.
    PubMed         Abstract available
29. ALWAN NA, Al-Aly Z
    Learning from long COVID: conceptualising action to tackle infection-associated non-communicable diseases.
    Lancet. 2024 Nov 6:S0140-6736(24)02256-6. doi: 10.1016/S0140-6736(24)02256.
    PubMed        
30. Global, regional, and national stillbirths at 20 weeks’ gestation or longer in 204 countries and territories, 1990-2021: findings from the Global Burden of Disease Study 2021.
    Lancet. 2024 Nov 4:S0140-6736(24)01925-1. doi: 10.1016/S0140-6736(24)01925.
    PubMed         Abstract available

    Lancet Infect Dis

31. ARORA P, Happle C, Kempf A, Nehlmeier I, et al
    Impact of JN.1 booster vaccination on neutralisation of SARS-CoV-2 variants KP.3.1.1 and XEC.
    Lancet Infect Dis. 2024 Nov 7:S1473-3099(24)00688.
    PubMed        
32. KAKU Y, Okumura K, Kawakubo S, Uriu K, et al
    Virological characteristics of the SARS-CoV-2 XEC variant.
    Lancet Infect Dis. 2024 Nov 6:S1473-3099(24)00731.
    PubMed        

    MMWR Morb Mortal Wkly Rep

33. LEFFERTS B, Bressler S, Keck JW, Desnoyers C, et al
    Nirsevimab Effectiveness Against Medically Attended Respiratory Syncytial Virus Illness and Hospitalization Among Alaska Native Children – Yukon-Kuskokwim Delta Region, Alaska, October 2023-June 2024.
    MMWR Morb Mortal Wkly Rep. 2024;73:1015-1021.
    PubMed         Abstract available
34. MINTA AA, Ferrari M, Antoni S, Lambert B, et al
    Progress Toward Measles Elimination – Worldwide, 2000-2023.
    MMWR Morb Mortal Wkly Rep. 2024;73:1036-1042.
    PubMed         Abstract available

    N Engl J Med

35. SCHMIDT P, Li Y, Popejoy M
    Immunobridging for Pemivibart, a Monoclonal Antibody for Prevention of Covid-19.
    N Engl J Med. 2024;391:1860-1862.
    PubMed        
36. WANG Q, Guo Y, Ho J, Ho DD, et al
    Activity of Research-Grade Pemivibart against Recent SARS-CoV-2 JN.1 Sublineages.
    N Engl J Med. 2024;391:1863-1864.
    PubMed        
37. JASTREBOFF AM, le Roux CW, Stefanski A, Aronne LJ, et al
    Tirzepatide for Obesity Treatment and Diabetes Prevention.
    N Engl J Med. 2024 Nov 13. doi: 10.1056/NEJMoa2410819.
    PubMed         Abstract available

    Nature

38. JIAN F, Wang J, Yisimayi A, Song W, et al
    Evolving antibody response to SARS-CoV-2 antigenic shift from XBB to JN.1.
    Nature. 2024 Nov 7. doi: 10.1038/s41586-024-08315.
    PubMed         Abstract available
39. SOLIMAN A
    US trust in scientists plunged during the pandemic – but it’s starting to recover.
    Nature. 2024 Nov 14. doi: 10.1038/d41586-024-03723.
    PubMed        

    Science

40. CHEN Z, Tsui JL, Gutierrez B, Busch Moreno S, et al
    COVID-19 pandemic interventions reshaped the global dispersal of seasonal influenza viruses.
    Science. 2024;386:eadq3003.
    PubMed         Abstract available
41. ROHANI P, Bahl J
    Collateral effects of pandemic control.
    Science. 2024;386:620-621.
    PubMed         Abstract available
42. VOGEL G
    ‘America first’ could affect health worldwide.
    Science. 2024;386:715.
    PubMed         Abstract available

#abstract #betacoronavirus #covid #COVID19 #health #news #research #sarbecovirus #sarsCov2

#Coronavirus Disease Research #References (by AMEDEO, Nov. 16 ’24)

1. AYYALA-SOMAYAJULA D, Dodge JL, Leventhal AM, Terrault NA, et al
   Trends in Alcohol Use After the COVID-19 Pandemic: A National Cross-Sectional Study.
   Ann Intern Med. 2024 Nov 12. doi: 10.7326/ANNALS-24-02157.
   PubMed        

   Antiviral Res

2. SAMA B, Selisko B, Falcou C, Fattorini V, et al
   The effects of Remdesivir’s functional groups on its antiviral potency and resistance against the SARS-CoV-2 polymerase.
   Antiviral Res. 2024 Nov 5:106034. doi: 10.1016/j.antiviral.2024.106034.
   PubMed         Abstract available

   BMJ

3. GREENHALGH T, Misak C, Payne R, Swann N, et al
   Patient involvement in developing clinical guidelines.
   BMJ. 2024;387:q2433.
   PubMed        

   Br J Anaesth

4. ANGELOPOULOS N, Staines J, Chamberlin M, Bates S, et al
   A narrative review of personal protective equipment gowns: lessons from COVID-19.
   Br J Anaesth. 2024 Nov 7:S0007-0912(24)00567-1. doi: 10.1016/j.bja.2024.
   PubMed         Abstract available

   Clin Infect Dis

5. GRANT R, de Kraker MEA, Buetti N, Jackson H, et al
   In-hospital outcomes of healthcare-associated COVID-19 (Omicron) versus healthcare-associated influenza: a retrospective, nationwide cohort study in Switzerland.
   Clin Infect Dis. 2024 Nov 13:ciae558. doi: 10.1093.
   PubMed         Abstract available
6. HAMMOND J, Leister-Tebbe H, Gardner A, Abreu P, et al
   Alleviation of COVID-19 Symptoms and Reduction in Healthcare Utilization Among High-Risk Patients Treated With Nirmatrelvir/Ritonavir (NMV/R): A phase 3 randomized trial.
   Clin Infect Dis. 2024 Nov 11:ciae551. doi: 10.1093.
   PubMed         Abstract available

   Emerg Infect Dis

7. CREPPAGE KE, Gallaway MS, Russell DA, Early JM, et al
   Global Emerging Infections Surveillance Program Contributions to Pandemic Preparedness and Response.
   Emerg Infect Dis. 2024;30:9-12.
   PubMed         Abstract available
8. MORTON LC, Rahman N, Bishop-Lilly KA
   Next-Generation Sequencing and Bioinformatics Consortium Approach to Genomic Surveillance.
   Emerg Infect Dis. 2024;30:13-18.
   PubMed         Abstract available
9. MUEHLEMAN D, Gruner B, Hogan V, Fanning P, et al
   Using SARS-CoV-2 Sequencing Data to Identify Reinfection Cases in the Global Emerging Infections Surveillance Program, United States.
   Emerg Infect Dis. 2024;30:53-61.
   PubMed         Abstract available
10. TINOCO YO, Osman TS, Ampuero JS, Gazo M, et al
    Respiratory Disease Surveillance in the Middle East and Latin America during the COVID-19 Pandemic, 2020-2022.
    Emerg Infect Dis. 2024;30:26-32.
    PubMed         Abstract available
11. ODUNDO EA, Kipkirui EC, Koech MC, Kirui MC, et al
    Azithromycin Resistance Patterns in Escherichia coli and Shigella before and after COVID-19, Kenya.
    Emerg Infect Dis. 2024;30:86-93.
    PubMed         Abstract available

    Int J Infect Dis

12. GRIFFITHS M, Hatabah D, Sullivan P, Mantus G, et al
    Corrigendum to “Incidence of SARS-CoV-2 seropositivity in pediatric healthcare workers prior to widespread vaccination: A 5-month longitudinal cohort study” [Internation Journal of Infectious Diseases, volume 144 (2024) 107064].
    Int J Infect Dis. 2024;149:107278.
    PubMed        
13. LASTRUCCI V, Pacifici M, Puglia M, Alderotti G, et al
    Erratum to ‘Seasonality and severity of respiratory syncytial virus during the COVID-19 pandemic: a dynamic cohort study’.
    Int J Infect Dis. 2024;149:107286.
    PubMed        

    Intensive Care Med

14. KESECIOGLU J, Rusinova K, Alampi D, Arabi YM, et al
    European Society of Intensive Care Medicine guidelines on end of life and palliative care in the intensive care unit.
    Intensive Care Med. 2024 Oct 3. doi: 10.1007/s00134-024-07579.
    PubMed         Abstract available
15. OLMOS M, Esperatti M, Fuentes N, Miranda Tirado A, et al
    Early physiologic changes after awake prone positioning predict clinical outcomes in patients with acute hypoxemic respiratory failure.
    Intensive Care Med. 2024 Nov 14. doi: 10.1007/s00134-024-07690.
    PubMed         Abstract available

    J Infect

16. DULFER EA, Fohse K, Taks EJM, Moorlag SJCFM, et al
    The effect of BCG vaccination in the elderly on infectious and non-infectious immune-mediated diseases.
    J Infect. 2024;89:106344.
    PubMed         Abstract available
17. HAN B, Du C, Deng M, Tang R, et al
    Real-world effectiveness and safety of simnotrelvir/ritonavir for COVID-19: A nationwide, multicenter, prospective, observational cohort study in China.
    J Infect. 2024 Nov 7:106339. doi: 10.1016/j.jinf.2024.106339.
    PubMed         Abstract available
18. FOONG KS
    Corrigendum to “The IL-6 hypothesis in COVID-19: A phase 2, randomised, double-blind, placebo-controlled study to evaluate the efficacy and safety of free IL-6 sequestration by the monoclonal antibody sirukumab in severe and critical COVID-19” [J Infe
    J Infect. 2024;89:106343.
    PubMed        

    J Med Virol

19. USTIUZHANINA MO, Boyko AA, Vavilova JD, Siniavin AE, et al
    The Antigen-Specific Response of NK Cells to SARS-CoV-2 Correlates With KIR2DS4 Expression.
    J Med Virol. 2024;96:e70057.
    PubMed         Abstract available
20. ZHANG C, Wang M, Sun S, Yi M, et al
    Impact of COVID-19 on the Prevalence and Drug Resistance of Bacteria Isolated From Bacterial Meningitis Cerebrospinal Fluid in Shandong Province: A Multicenter Retrospective Study.
    J Med Virol. 2024;96:e70063.
    PubMed         Abstract available
21. ESPI M, Charmetant X, Benotmane I, Lefsihane K, et al
    Memory B Cells Provide Long-Term Protection to Vaccinated Kidney Transplant Recipients Against SARS-CoV-2 Variants.
    J Med Virol. 2024;96:e70037.
    PubMed         Abstract available
22. FACCO JV, Addas-Carvalho M, Duarte ADSS, Zangirolami AB, et al
    HLA-B*15 Is Associated With SARS-CoV-2 Infection in a Brazilian Population.
    J Med Virol. 2024;96:e70028.
    PubMed         Abstract available
23. WANG N, Lin Q, Fan H, Wang Y, et al
    BIC/FTC/TAF Benefits People Living With HIV After Omicron Breakthrough Infection in Shortening Duration of Symptoms, Enhancing Specific Immune Response and Increasing Total CD4 Cells.
    J Med Virol. 2024;96:e70036.
    PubMed         Abstract available
24. YE C, Tian Y, Huo D, Zhang T, et al
    Changes in Epidemics of Respiratory Viral Infections Resulted From the COVID-19 Pandemic in Shanghai.
    J Med Virol. 2024;96:e70034.
    PubMed         Abstract available

    J Virol

25. CHEN Y, Ou X, Li P, Zan F, et al
    Identification of the critical residues of TMPRSS2 for entry and host range of human coronavirus HKU1.
    J Virol. 2024 Nov 11:e0158724. doi: 10.1128/jvi.01587.
    PubMed         Abstract available
26. STEIGMANN JC, Zhou X, Suttenberg LN, Salman I, et al
    Effects of immunoproteasome inhibition on acute respiratory infection with murine hepatitis virus strain 1.
    J Virol. 2024 Nov 7:e0123824. doi: 10.1128/jvi.01238.
    PubMed         Abstract available

    JAMA

27. ANDERER S
    FDA Authorizes First At-Home COVID-19 and Flu Combo Test.
    JAMA. 2024 Nov 8. doi: 10.1001/jama.2024.22561.
    PubMed        

    Lancet

28. DWYER-LINDGREN L, Kendrick P, Baumann MM, Li Z, et al
    Disparities in wellbeing in the USA by race and ethnicity, age, sex, and location, 2008-21: an analysis using the Human Development Index.
    Lancet. 2024 Nov 6:S0140-6736(24)01757-4. doi: 10.1016/S0140-6736(24)01757.
    PubMed         Abstract available
29. ALWAN NA, Al-Aly Z
    Learning from long COVID: conceptualising action to tackle infection-associated non-communicable diseases.
    Lancet. 2024 Nov 6:S0140-6736(24)02256-6. doi: 10.1016/S0140-6736(24)02256.
    PubMed        
30. Global, regional, and national stillbirths at 20 weeks’ gestation or longer in 204 countries and territories, 1990-2021: findings from the Global Burden of Disease Study 2021.
    Lancet. 2024 Nov 4:S0140-6736(24)01925-1. doi: 10.1016/S0140-6736(24)01925.
    PubMed         Abstract available

    Lancet Infect Dis

31. ARORA P, Happle C, Kempf A, Nehlmeier I, et al
    Impact of JN.1 booster vaccination on neutralisation of SARS-CoV-2 variants KP.3.1.1 and XEC.
    Lancet Infect Dis. 2024 Nov 7:S1473-3099(24)00688.
    PubMed        
32. KAKU Y, Okumura K, Kawakubo S, Uriu K, et al
    Virological characteristics of the SARS-CoV-2 XEC variant.
    Lancet Infect Dis. 2024 Nov 6:S1473-3099(24)00731.
    PubMed        

    MMWR Morb Mortal Wkly Rep

33. LEFFERTS B, Bressler S, Keck JW, Desnoyers C, et al
    Nirsevimab Effectiveness Against Medically Attended Respiratory Syncytial Virus Illness and Hospitalization Among Alaska Native Children – Yukon-Kuskokwim Delta Region, Alaska, October 2023-June 2024.
    MMWR Morb Mortal Wkly Rep. 2024;73:1015-1021.
    PubMed         Abstract available
34. MINTA AA, Ferrari M, Antoni S, Lambert B, et al
    Progress Toward Measles Elimination – Worldwide, 2000-2023.
    MMWR Morb Mortal Wkly Rep. 2024;73:1036-1042.
    PubMed         Abstract available

    N Engl J Med

35. SCHMIDT P, Li Y, Popejoy M
    Immunobridging for Pemivibart, a Monoclonal Antibody for Prevention of Covid-19.
    N Engl J Med. 2024;391:1860-1862.
    PubMed        
36. WANG Q, Guo Y, Ho J, Ho DD, et al
    Activity of Research-Grade Pemivibart against Recent SARS-CoV-2 JN.1 Sublineages.
    N Engl J Med. 2024;391:1863-1864.
    PubMed        
37. JASTREBOFF AM, le Roux CW, Stefanski A, Aronne LJ, et al
    Tirzepatide for Obesity Treatment and Diabetes Prevention.
    N Engl J Med. 2024 Nov 13. doi: 10.1056/NEJMoa2410819.
    PubMed         Abstract available

    Nature

38. JIAN F, Wang J, Yisimayi A, Song W, et al
    Evolving antibody response to SARS-CoV-2 antigenic shift from XBB to JN.1.
    Nature. 2024 Nov 7. doi: 10.1038/s41586-024-08315.
    PubMed         Abstract available
39. SOLIMAN A
    US trust in scientists plunged during the pandemic – but it’s starting to recover.
    Nature. 2024 Nov 14. doi: 10.1038/d41586-024-03723.
    PubMed        

    Science

40. CHEN Z, Tsui JL, Gutierrez B, Busch Moreno S, et al
    COVID-19 pandemic interventions reshaped the global dispersal of seasonal influenza viruses.
    Science. 2024;386:eadq3003.
    PubMed         Abstract available
41. ROHANI P, Bahl J
    Collateral effects of pandemic control.
    Science. 2024;386:620-621.
    PubMed         Abstract available
42. VOGEL G
    ‘America first’ could affect health worldwide.
    Science. 2024;386:715.
    PubMed         Abstract available

#abstract #betacoronavirus #covid #COVID19 #health #news #research #sarbecovirus #sarsCov2

#Coronavirus Disease Research #References (by AMEDEO, Nov. 16 ’24)

1. AYYALA-SOMAYAJULA D, Dodge JL, Leventhal AM, Terrault NA, et al
   Trends in Alcohol Use After the COVID-19 Pandemic: A National Cross-Sectional Study.
   Ann Intern Med. 2024 Nov 12. doi: 10.7326/ANNALS-24-02157.
   PubMed        

   Antiviral Res

2. SAMA B, Selisko B, Falcou C, Fattorini V, et al
   The effects of Remdesivir’s functional groups on its antiviral potency and resistance against the SARS-CoV-2 polymerase.
   Antiviral Res. 2024 Nov 5:106034. doi: 10.1016/j.antiviral.2024.106034.
   PubMed         Abstract available

   BMJ

3. GREENHALGH T, Misak C, Payne R, Swann N, et al
   Patient involvement in developing clinical guidelines.
   BMJ. 2024;387:q2433.
   PubMed        

   Br J Anaesth

4. ANGELOPOULOS N, Staines J, Chamberlin M, Bates S, et al
   A narrative review of personal protective equipment gowns: lessons from COVID-19.
   Br J Anaesth. 2024 Nov 7:S0007-0912(24)00567-1. doi: 10.1016/j.bja.2024.
   PubMed         Abstract available

   Clin Infect Dis

5. GRANT R, de Kraker MEA, Buetti N, Jackson H, et al
   In-hospital outcomes of healthcare-associated COVID-19 (Omicron) versus healthcare-associated influenza: a retrospective, nationwide cohort study in Switzerland.
   Clin Infect Dis. 2024 Nov 13:ciae558. doi: 10.1093.
   PubMed         Abstract available
6. HAMMOND J, Leister-Tebbe H, Gardner A, Abreu P, et al
   Alleviation of COVID-19 Symptoms and Reduction in Healthcare Utilization Among High-Risk Patients Treated With Nirmatrelvir/Ritonavir (NMV/R): A phase 3 randomized trial.
   Clin Infect Dis. 2024 Nov 11:ciae551. doi: 10.1093.
   PubMed         Abstract available

   Emerg Infect Dis

7. CREPPAGE KE, Gallaway MS, Russell DA, Early JM, et al
   Global Emerging Infections Surveillance Program Contributions to Pandemic Preparedness and Response.
   Emerg Infect Dis. 2024;30:9-12.
   PubMed         Abstract available
8. MORTON LC, Rahman N, Bishop-Lilly KA
   Next-Generation Sequencing and Bioinformatics Consortium Approach to Genomic Surveillance.
   Emerg Infect Dis. 2024;30:13-18.
   PubMed         Abstract available
9. MUEHLEMAN D, Gruner B, Hogan V, Fanning P, et al
   Using SARS-CoV-2 Sequencing Data to Identify Reinfection Cases in the Global Emerging Infections Surveillance Program, United States.
   Emerg Infect Dis. 2024;30:53-61.
   PubMed         Abstract available
10. TINOCO YO, Osman TS, Ampuero JS, Gazo M, et al
    Respiratory Disease Surveillance in the Middle East and Latin America during the COVID-19 Pandemic, 2020-2022.
    Emerg Infect Dis. 2024;30:26-32.
    PubMed         Abstract available
11. ODUNDO EA, Kipkirui EC, Koech MC, Kirui MC, et al
    Azithromycin Resistance Patterns in Escherichia coli and Shigella before and after COVID-19, Kenya.
    Emerg Infect Dis. 2024;30:86-93.
    PubMed         Abstract available

    Int J Infect Dis

12. GRIFFITHS M, Hatabah D, Sullivan P, Mantus G, et al
    Corrigendum to “Incidence of SARS-CoV-2 seropositivity in pediatric healthcare workers prior to widespread vaccination: A 5-month longitudinal cohort study” [Internation Journal of Infectious Diseases, volume 144 (2024) 107064].
    Int J Infect Dis. 2024;149:107278.
    PubMed        
13. LASTRUCCI V, Pacifici M, Puglia M, Alderotti G, et al
    Erratum to ‘Seasonality and severity of respiratory syncytial virus during the COVID-19 pandemic: a dynamic cohort study’.
    Int J Infect Dis. 2024;149:107286.
    PubMed        

    Intensive Care Med

14. KESECIOGLU J, Rusinova K, Alampi D, Arabi YM, et al
    European Society of Intensive Care Medicine guidelines on end of life and palliative care in the intensive care unit.
    Intensive Care Med. 2024 Oct 3. doi: 10.1007/s00134-024-07579.
    PubMed         Abstract available
15. OLMOS M, Esperatti M, Fuentes N, Miranda Tirado A, et al
    Early physiologic changes after awake prone positioning predict clinical outcomes in patients with acute hypoxemic respiratory failure.
    Intensive Care Med. 2024 Nov 14. doi: 10.1007/s00134-024-07690.
    PubMed         Abstract available

    J Infect

16. DULFER EA, Fohse K, Taks EJM, Moorlag SJCFM, et al
    The effect of BCG vaccination in the elderly on infectious and non-infectious immune-mediated diseases.
    J Infect. 2024;89:106344.
    PubMed         Abstract available
17. HAN B, Du C, Deng M, Tang R, et al
    Real-world effectiveness and safety of simnotrelvir/ritonavir for COVID-19: A nationwide, multicenter, prospective, observational cohort study in China.
    J Infect. 2024 Nov 7:106339. doi: 10.1016/j.jinf.2024.106339.
    PubMed         Abstract available
18. FOONG KS
    Corrigendum to “The IL-6 hypothesis in COVID-19: A phase 2, randomised, double-blind, placebo-controlled study to evaluate the efficacy and safety of free IL-6 sequestration by the monoclonal antibody sirukumab in severe and critical COVID-19” [J Infe
    J Infect. 2024;89:106343.
    PubMed        

    J Med Virol

19. USTIUZHANINA MO, Boyko AA, Vavilova JD, Siniavin AE, et al
    The Antigen-Specific Response of NK Cells to SARS-CoV-2 Correlates With KIR2DS4 Expression.
    J Med Virol. 2024;96:e70057.
    PubMed         Abstract available
20. ZHANG C, Wang M, Sun S, Yi M, et al
    Impact of COVID-19 on the Prevalence and Drug Resistance of Bacteria Isolated From Bacterial Meningitis Cerebrospinal Fluid in Shandong Province: A Multicenter Retrospective Study.
    J Med Virol. 2024;96:e70063.
    PubMed         Abstract available
21. ESPI M, Charmetant X, Benotmane I, Lefsihane K, et al
    Memory B Cells Provide Long-Term Protection to Vaccinated Kidney Transplant Recipients Against SARS-CoV-2 Variants.
    J Med Virol. 2024;96:e70037.
    PubMed         Abstract available
22. FACCO JV, Addas-Carvalho M, Duarte ADSS, Zangirolami AB, et al
    HLA-B*15 Is Associated With SARS-CoV-2 Infection in a Brazilian Population.
    J Med Virol. 2024;96:e70028.
    PubMed         Abstract available
23. WANG N, Lin Q, Fan H, Wang Y, et al
    BIC/FTC/TAF Benefits People Living With HIV After Omicron Breakthrough Infection in Shortening Duration of Symptoms, Enhancing Specific Immune Response and Increasing Total CD4 Cells.
    J Med Virol. 2024;96:e70036.
    PubMed         Abstract available
24. YE C, Tian Y, Huo D, Zhang T, et al
    Changes in Epidemics of Respiratory Viral Infections Resulted From the COVID-19 Pandemic in Shanghai.
    J Med Virol. 2024;96:e70034.
    PubMed         Abstract available

    J Virol

25. CHEN Y, Ou X, Li P, Zan F, et al
    Identification of the critical residues of TMPRSS2 for entry and host range of human coronavirus HKU1.
    J Virol. 2024 Nov 11:e0158724. doi: 10.1128/jvi.01587.
    PubMed         Abstract available
26. STEIGMANN JC, Zhou X, Suttenberg LN, Salman I, et al
    Effects of immunoproteasome inhibition on acute respiratory infection with murine hepatitis virus strain 1.
    J Virol. 2024 Nov 7:e0123824. doi: 10.1128/jvi.01238.
    PubMed         Abstract available

    JAMA

27. ANDERER S
    FDA Authorizes First At-Home COVID-19 and Flu Combo Test.
    JAMA. 2024 Nov 8. doi: 10.1001/jama.2024.22561.
    PubMed        

    Lancet

28. DWYER-LINDGREN L, Kendrick P, Baumann MM, Li Z, et al
    Disparities in wellbeing in the USA by race and ethnicity, age, sex, and location, 2008-21: an analysis using the Human Development Index.
    Lancet. 2024 Nov 6:S0140-6736(24)01757-4. doi: 10.1016/S0140-6736(24)01757.
    PubMed         Abstract available
29. ALWAN NA, Al-Aly Z
    Learning from long COVID: conceptualising action to tackle infection-associated non-communicable diseases.
    Lancet. 2024 Nov 6:S0140-6736(24)02256-6. doi: 10.1016/S0140-6736(24)02256.
    PubMed        
30. Global, regional, and national stillbirths at 20 weeks’ gestation or longer in 204 countries and territories, 1990-2021: findings from the Global Burden of Disease Study 2021.
    Lancet. 2024 Nov 4:S0140-6736(24)01925-1. doi: 10.1016/S0140-6736(24)01925.
    PubMed         Abstract available

    Lancet Infect Dis

31. ARORA P, Happle C, Kempf A, Nehlmeier I, et al
    Impact of JN.1 booster vaccination on neutralisation of SARS-CoV-2 variants KP.3.1.1 and XEC.
    Lancet Infect Dis. 2024 Nov 7:S1473-3099(24)00688.
    PubMed        
32. KAKU Y, Okumura K, Kawakubo S, Uriu K, et al
    Virological characteristics of the SARS-CoV-2 XEC variant.
    Lancet Infect Dis. 2024 Nov 6:S1473-3099(24)00731.
    PubMed        

    MMWR Morb Mortal Wkly Rep

33. LEFFERTS B, Bressler S, Keck JW, Desnoyers C, et al
    Nirsevimab Effectiveness Against Medically Attended Respiratory Syncytial Virus Illness and Hospitalization Among Alaska Native Children – Yukon-Kuskokwim Delta Region, Alaska, October 2023-June 2024.
    MMWR Morb Mortal Wkly Rep. 2024;73:1015-1021.
    PubMed         Abstract available
34. MINTA AA, Ferrari M, Antoni S, Lambert B, et al
    Progress Toward Measles Elimination – Worldwide, 2000-2023.
    MMWR Morb Mortal Wkly Rep. 2024;73:1036-1042.
    PubMed         Abstract available

    N Engl J Med

35. SCHMIDT P, Li Y, Popejoy M
    Immunobridging for Pemivibart, a Monoclonal Antibody for Prevention of Covid-19.
    N Engl J Med. 2024;391:1860-1862.
    PubMed        
36. WANG Q, Guo Y, Ho J, Ho DD, et al
    Activity of Research-Grade Pemivibart against Recent SARS-CoV-2 JN.1 Sublineages.
    N Engl J Med. 2024;391:1863-1864.
    PubMed        
37. JASTREBOFF AM, le Roux CW, Stefanski A, Aronne LJ, et al
    Tirzepatide for Obesity Treatment and Diabetes Prevention.
    N Engl J Med. 2024 Nov 13. doi: 10.1056/NEJMoa2410819.
    PubMed         Abstract available

    Nature

38. JIAN F, Wang J, Yisimayi A, Song W, et al
    Evolving antibody response to SARS-CoV-2 antigenic shift from XBB to JN.1.
    Nature. 2024 Nov 7. doi: 10.1038/s41586-024-08315.
    PubMed         Abstract available
39. SOLIMAN A
    US trust in scientists plunged during the pandemic – but it’s starting to recover.
    Nature. 2024 Nov 14. doi: 10.1038/d41586-024-03723.
    PubMed        

    Science

40. CHEN Z, Tsui JL, Gutierrez B, Busch Moreno S, et al
    COVID-19 pandemic interventions reshaped the global dispersal of seasonal influenza viruses.
    Science. 2024;386:eadq3003.
    PubMed         Abstract available
41. ROHANI P, Bahl J
    Collateral effects of pandemic control.
    Science. 2024;386:620-621.
    PubMed         Abstract available
42. VOGEL G
    ‘America first’ could affect health worldwide.
    Science. 2024;386:715.
    PubMed         Abstract available

#abstract #betacoronavirus #covid #COVID19 #health #news #research #sarbecovirus #sarsCov2

#Coronavirus Disease Research #References (by AMEDEO, Nov. 16 ’24)

1. AYYALA-SOMAYAJULA D, Dodge JL, Leventhal AM, Terrault NA, et al
   Trends in Alcohol Use After the COVID-19 Pandemic: A National Cross-Sectional Study.
   Ann Intern Med. 2024 Nov 12. doi: 10.7326/ANNALS-24-02157.
   PubMed        

   Antiviral Res

2. SAMA B, Selisko B, Falcou C, Fattorini V, et al
   The effects of Remdesivir’s functional groups on its antiviral potency and resistance against the SARS-CoV-2 polymerase.
   Antiviral Res. 2024 Nov 5:106034. doi: 10.1016/j.antiviral.2024.106034.
   PubMed         Abstract available

   BMJ

3. GREENHALGH T, Misak C, Payne R, Swann N, et al
   Patient involvement in developing clinical guidelines.
   BMJ. 2024;387:q2433.
   PubMed        

   Br J Anaesth

4. ANGELOPOULOS N, Staines J, Chamberlin M, Bates S, et al
   A narrative review of personal protective equipment gowns: lessons from COVID-19.
   Br J Anaesth. 2024 Nov 7:S0007-0912(24)00567-1. doi: 10.1016/j.bja.2024.
   PubMed         Abstract available

   Clin Infect Dis

5. GRANT R, de Kraker MEA, Buetti N, Jackson H, et al
   In-hospital outcomes of healthcare-associated COVID-19 (Omicron) versus healthcare-associated influenza: a retrospective, nationwide cohort study in Switzerland.
   Clin Infect Dis. 2024 Nov 13:ciae558. doi: 10.1093.
   PubMed         Abstract available
6. HAMMOND J, Leister-Tebbe H, Gardner A, Abreu P, et al
   Alleviation of COVID-19 Symptoms and Reduction in Healthcare Utilization Among High-Risk Patients Treated With Nirmatrelvir/Ritonavir (NMV/R): A phase 3 randomized trial.
   Clin Infect Dis. 2024 Nov 11:ciae551. doi: 10.1093.
   PubMed         Abstract available

   Emerg Infect Dis

7. CREPPAGE KE, Gallaway MS, Russell DA, Early JM, et al
   Global Emerging Infections Surveillance Program Contributions to Pandemic Preparedness and Response.
   Emerg Infect Dis. 2024;30:9-12.
   PubMed         Abstract available
8. MORTON LC, Rahman N, Bishop-Lilly KA
   Next-Generation Sequencing and Bioinformatics Consortium Approach to Genomic Surveillance.
   Emerg Infect Dis. 2024;30:13-18.
   PubMed         Abstract available
9. MUEHLEMAN D, Gruner B, Hogan V, Fanning P, et al
   Using SARS-CoV-2 Sequencing Data to Identify Reinfection Cases in the Global Emerging Infections Surveillance Program, United States.
   Emerg Infect Dis. 2024;30:53-61.
   PubMed         Abstract available
10. TINOCO YO, Osman TS, Ampuero JS, Gazo M, et al
    Respiratory Disease Surveillance in the Middle East and Latin America during the COVID-19 Pandemic, 2020-2022.
    Emerg Infect Dis. 2024;30:26-32.
    PubMed         Abstract available
11. ODUNDO EA, Kipkirui EC, Koech MC, Kirui MC, et al
    Azithromycin Resistance Patterns in Escherichia coli and Shigella before and after COVID-19, Kenya.
    Emerg Infect Dis. 2024;30:86-93.
    PubMed         Abstract available

    Int J Infect Dis

12. GRIFFITHS M, Hatabah D, Sullivan P, Mantus G, et al
    Corrigendum to “Incidence of SARS-CoV-2 seropositivity in pediatric healthcare workers prior to widespread vaccination: A 5-month longitudinal cohort study” [Internation Journal of Infectious Diseases, volume 144 (2024) 107064].
    Int J Infect Dis. 2024;149:107278.
    PubMed        
13. LASTRUCCI V, Pacifici M, Puglia M, Alderotti G, et al
    Erratum to ‘Seasonality and severity of respiratory syncytial virus during the COVID-19 pandemic: a dynamic cohort study’.
    Int J Infect Dis. 2024;149:107286.
    PubMed        

    Intensive Care Med

14. KESECIOGLU J, Rusinova K, Alampi D, Arabi YM, et al
    European Society of Intensive Care Medicine guidelines on end of life and palliative care in the intensive care unit.
    Intensive Care Med. 2024 Oct 3. doi: 10.1007/s00134-024-07579.
    PubMed         Abstract available
15. OLMOS M, Esperatti M, Fuentes N, Miranda Tirado A, et al
    Early physiologic changes after awake prone positioning predict clinical outcomes in patients with acute hypoxemic respiratory failure.
    Intensive Care Med. 2024 Nov 14. doi: 10.1007/s00134-024-07690.
    PubMed         Abstract available

    J Infect

16. DULFER EA, Fohse K, Taks EJM, Moorlag SJCFM, et al
    The effect of BCG vaccination in the elderly on infectious and non-infectious immune-mediated diseases.
    J Infect. 2024;89:106344.
    PubMed         Abstract available
17. HAN B, Du C, Deng M, Tang R, et al
    Real-world effectiveness and safety of simnotrelvir/ritonavir for COVID-19: A nationwide, multicenter, prospective, observational cohort study in China.
    J Infect. 2024 Nov 7:106339. doi: 10.1016/j.jinf.2024.106339.
    PubMed         Abstract available
18. FOONG KS
    Corrigendum to “The IL-6 hypothesis in COVID-19: A phase 2, randomised, double-blind, placebo-controlled study to evaluate the efficacy and safety of free IL-6 sequestration by the monoclonal antibody sirukumab in severe and critical COVID-19” [J Infe
    J Infect. 2024;89:106343.
    PubMed        

    J Med Virol

19. USTIUZHANINA MO, Boyko AA, Vavilova JD, Siniavin AE, et al
    The Antigen-Specific Response of NK Cells to SARS-CoV-2 Correlates With KIR2DS4 Expression.
    J Med Virol. 2024;96:e70057.
    PubMed         Abstract available
20. ZHANG C, Wang M, Sun S, Yi M, et al
    Impact of COVID-19 on the Prevalence and Drug Resistance of Bacteria Isolated From Bacterial Meningitis Cerebrospinal Fluid in Shandong Province: A Multicenter Retrospective Study.
    J Med Virol. 2024;96:e70063.
    PubMed         Abstract available
21. ESPI M, Charmetant X, Benotmane I, Lefsihane K, et al
    Memory B Cells Provide Long-Term Protection to Vaccinated Kidney Transplant Recipients Against SARS-CoV-2 Variants.
    J Med Virol. 2024;96:e70037.
    PubMed         Abstract available
22. FACCO JV, Addas-Carvalho M, Duarte ADSS, Zangirolami AB, et al
    HLA-B*15 Is Associated With SARS-CoV-2 Infection in a Brazilian Population.
    J Med Virol. 2024;96:e70028.
    PubMed         Abstract available
23. WANG N, Lin Q, Fan H, Wang Y, et al
    BIC/FTC/TAF Benefits People Living With HIV After Omicron Breakthrough Infection in Shortening Duration of Symptoms, Enhancing Specific Immune Response and Increasing Total CD4 Cells.
    J Med Virol. 2024;96:e70036.
    PubMed         Abstract available
24. YE C, Tian Y, Huo D, Zhang T, et al
    Changes in Epidemics of Respiratory Viral Infections Resulted From the COVID-19 Pandemic in Shanghai.
    J Med Virol. 2024;96:e70034.
    PubMed         Abstract available

    J Virol

25. CHEN Y, Ou X, Li P, Zan F, et al
    Identification of the critical residues of TMPRSS2 for entry and host range of human coronavirus HKU1.
    J Virol. 2024 Nov 11:e0158724. doi: 10.1128/jvi.01587.
    PubMed         Abstract available
26. STEIGMANN JC, Zhou X, Suttenberg LN, Salman I, et al
    Effects of immunoproteasome inhibition on acute respiratory infection with murine hepatitis virus strain 1.
    J Virol. 2024 Nov 7:e0123824. doi: 10.1128/jvi.01238.
    PubMed         Abstract available

    JAMA

27. ANDERER S
    FDA Authorizes First At-Home COVID-19 and Flu Combo Test.
    JAMA. 2024 Nov 8. doi: 10.1001/jama.2024.22561.
    PubMed        

    Lancet

28. DWYER-LINDGREN L, Kendrick P, Baumann MM, Li Z, et al
    Disparities in wellbeing in the USA by race and ethnicity, age, sex, and location, 2008-21: an analysis using the Human Development Index.
    Lancet. 2024 Nov 6:S0140-6736(24)01757-4. doi: 10.1016/S0140-6736(24)01757.
    PubMed         Abstract available
29. ALWAN NA, Al-Aly Z
    Learning from long COVID: conceptualising action to tackle infection-associated non-communicable diseases.
    Lancet. 2024 Nov 6:S0140-6736(24)02256-6. doi: 10.1016/S0140-6736(24)02256.
    PubMed        
30. Global, regional, and national stillbirths at 20 weeks’ gestation or longer in 204 countries and territories, 1990-2021: findings from the Global Burden of Disease Study 2021.
    Lancet. 2024 Nov 4:S0140-6736(24)01925-1. doi: 10.1016/S0140-6736(24)01925.
    PubMed         Abstract available

    Lancet Infect Dis

31. ARORA P, Happle C, Kempf A, Nehlmeier I, et al
    Impact of JN.1 booster vaccination on neutralisation of SARS-CoV-2 variants KP.3.1.1 and XEC.
    Lancet Infect Dis. 2024 Nov 7:S1473-3099(24)00688.
    PubMed        
32. KAKU Y, Okumura K, Kawakubo S, Uriu K, et al
    Virological characteristics of the SARS-CoV-2 XEC variant.
    Lancet Infect Dis. 2024 Nov 6:S1473-3099(24)00731.
    PubMed        

    MMWR Morb Mortal Wkly Rep

33. LEFFERTS B, Bressler S, Keck JW, Desnoyers C, et al
    Nirsevimab Effectiveness Against Medically Attended Respiratory Syncytial Virus Illness and Hospitalization Among Alaska Native Children – Yukon-Kuskokwim Delta Region, Alaska, October 2023-June 2024.
    MMWR Morb Mortal Wkly Rep. 2024;73:1015-1021.
    PubMed         Abstract available
34. MINTA AA, Ferrari M, Antoni S, Lambert B, et al
    Progress Toward Measles Elimination – Worldwide, 2000-2023.
    MMWR Morb Mortal Wkly Rep. 2024;73:1036-1042.
    PubMed         Abstract available

    N Engl J Med

35. SCHMIDT P, Li Y, Popejoy M
    Immunobridging for Pemivibart, a Monoclonal Antibody for Prevention of Covid-19.
    N Engl J Med. 2024;391:1860-1862.
    PubMed        
36. WANG Q, Guo Y, Ho J, Ho DD, et al
    Activity of Research-Grade Pemivibart against Recent SARS-CoV-2 JN.1 Sublineages.
    N Engl J Med. 2024;391:1863-1864.
    PubMed        
37. JASTREBOFF AM, le Roux CW, Stefanski A, Aronne LJ, et al
    Tirzepatide for Obesity Treatment and Diabetes Prevention.
    N Engl J Med. 2024 Nov 13. doi: 10.1056/NEJMoa2410819.
    PubMed         Abstract available

    Nature

38. JIAN F, Wang J, Yisimayi A, Song W, et al
    Evolving antibody response to SARS-CoV-2 antigenic shift from XBB to JN.1.
    Nature. 2024 Nov 7. doi: 10.1038/s41586-024-08315.
    PubMed         Abstract available
39. SOLIMAN A
    US trust in scientists plunged during the pandemic – but it’s starting to recover.
    Nature. 2024 Nov 14. doi: 10.1038/d41586-024-03723.
    PubMed        

    Science

40. CHEN Z, Tsui JL, Gutierrez B, Busch Moreno S, et al
    COVID-19 pandemic interventions reshaped the global dispersal of seasonal influenza viruses.
    Science. 2024;386:eadq3003.
    PubMed         Abstract available
41. ROHANI P, Bahl J
    Collateral effects of pandemic control.
    Science. 2024;386:620-621.
    PubMed         Abstract available
42. VOGEL G
    ‘America first’ could affect health worldwide.
    Science. 2024;386:715.
    PubMed         Abstract available

#abstract #betacoronavirus #covid #COVID19 #health #news #research #sarbecovirus #sarsCov2

Source: npj Vaccines, https://www.nature.com/articles/s41541-024-01016-6

Abstract
We report SARS-CoV-2 KP.1, KP.1.1, KP.2 and KP.3 neutralizing antibody titers. They displayed increased immune evasion compared to JN.1, especially KP.1 and KP.3, for participants who experienced BF.7/BA.5.2 breakthrough infection or received bivalent (delta/BA.5) vaccine boosting. Second XBB sub-variants breakthrough infection enhanced the neutralization responses. HK.3-JN.1 RBD-heterodimer induced balanced and potent neutralizing responses against recently-circulating SARS-CoV-2 sub-variants in mice, supporting to replace the COVID-19 antigen containing JN.1 or its sub-variants.

_____

https://etidioh.wordpress.com/2024/11/11/neutralization-of-sars-cov-2-kp1-kp11-kp2-and-kp3-by-human-and-murine-sera/

#abstract #betacoronavirus #COVID19 #research #sarbecovirus #sarsCov2 #vaccines

Source: npj Vaccines, https://www.nature.com/articles/s41541-024-01016-6

Abstract
We report SARS-CoV-2 KP.1, KP.1.1, KP.2 and KP.3 neutralizing antibody titers. They displayed increased immune evasion compared to JN.1, especially KP.1 and KP.3, for participants who experienced BF.7/BA.5.2 breakthrough infection or received bivalent (delta/BA.5) vaccine boosting. Second XBB sub-variants breakthrough infection enhanced the neutralization responses. HK.3-JN.1 RBD-heterodimer induced balanced and potent neutralizing responses against recently-circulating SARS-CoV-2 sub-variants in mice, supporting to replace the COVID-19 antigen containing JN.1 or its sub-variants.

_____

https://etidioh.wordpress.com/2024/11/11/neutralization-of-sars-cov-2-kp1-kp11-kp2-and-kp3-by-human-and-murine-sera/

#abstract #betacoronavirus #COVID19 #research #sarbecovirus #sarsCov2 #vaccines

Source: npj Vaccines, https://www.nature.com/articles/s41541-024-01016-6

Abstract
We report SARS-CoV-2 KP.1, KP.1.1, KP.2 and KP.3 neutralizing antibody titers. They displayed increased immune evasion compared to JN.1, especially KP.1 and KP.3, for participants who experienced BF.7/BA.5.2 breakthrough infection or received bivalent (delta/BA.5) vaccine boosting. Second XBB sub-variants breakthrough infection enhanced the neutralization responses. HK.3-JN.1 RBD-heterodimer induced balanced and potent neutralizing responses against recently-circulating SARS-CoV-2 sub-variants in mice, supporting to replace the COVID-19 antigen containing JN.1 or its sub-variants.

_____

https://etidioh.wordpress.com/2024/11/11/neutralization-of-sars-cov-2-kp1-kp11-kp2-and-kp3-by-human-and-murine-sera/

#abstract #betacoronavirus #COVID19 #research #sarbecovirus #sarsCov2 #vaccines

Source: npj Vaccines, https://www.nature.com/articles/s41541-024-01016-6

Abstract
We report SARS-CoV-2 KP.1, KP.1.1, KP.2 and KP.3 neutralizing antibody titers. They displayed increased immune evasion compared to JN.1, especially KP.1 and KP.3, for participants who experienced BF.7/BA.5.2 breakthrough infection or received bivalent (delta/BA.5) vaccine boosting. Second XBB sub-variants breakthrough infection enhanced the neutralization responses. HK.3-JN.1 RBD-heterodimer induced balanced and potent neutralizing responses against recently-circulating SARS-CoV-2 sub-variants in mice, supporting to replace the COVID-19 antigen containing JN.1 or its sub-variants.

_____

https://etidioh.wordpress.com/2024/11/11/neutralization-of-sars-cov-2-kp1-kp11-kp2-and-kp3-by-human-and-murine-sera/

#abstract #betacoronavirus #COVID19 #research #sarbecovirus #sarsCov2 #vaccines

1. SELINGER S
   Patients surviving COVID-19 had lower risk for long COVID in the Omicron vs. earlier eras.
   Ann Intern Med. 2024 Nov 5. doi: 10.7326/ANNALS-24-02441.
   PubMed         Abstract available

   BMJ

2. BARRETT A
   Covid-19: Australian inquiry calls for establishment of a national centre for disease control and action to tackle inequities.
   BMJ. 2024;387:q2420.
   PubMed        

   Clin Infect Dis

3. MORTEZAVI M, Sloan A, Singh RSP, Chen LF, et al
   Virologic Response and Safety of Ibuzatrelvir, a Novel SARS-CoV-2 Antiviral, in Adults With COVID-19.
   Clin Infect Dis. 2024 Nov 2:ciae529. doi: 10.1093.
   PubMed         Abstract available

   Int J Infect Dis

4. NAVEED Z, Li J, Wilton J, Naus M, et al
   Healthcare utilization among COVID-19 mRNA vaccine-associated myocarditis cases: a matched retrospective cohort study.
   Int J Infect Dis. 2024 Nov 1:107287. doi: 10.1016/j.ijid.2024.107287.
   PubMed         Abstract available
5. EPSTEIN-SHUMAN A, Hunt JH, Caturegli P, Winguth P, et al
   Autoantibodies Directed Against Interferon Alpha, Nuclear Antigens, Cardiolipin, and Beta 2 Glycoprotein 1 Are Not Induced By SARS-CoV-2 or Associated with Long COVID.
   Int J Infect Dis. 2024 Nov 1:107289. doi: 10.1016/j.ijid.2024.107289.
   PubMed         Abstract available

   Intensive Care Med

6. WANG Y, Hao S, Song J, Zhong M, et al
   Reflections on awake prone positioning in COVID-19: considerations on body inclination, respiratory support, and patient variability.
   Intensive Care Med. 2024 Nov 4. doi: 10.1007/s00134-024-07710.
   PubMed        

   J Infect

7. WANG H, Zhou Y, Chu L, Chen K, et al
   Guardian-driven influenza vaccination intentions for children post-COVID-19 in the 2024-2025 season: The positive spillover effects.
   J Infect. 2024;89:106333.
   PubMed        
8. HO A, McInnes N, Blunsum A, Quinn J, et al
   Near real-time severe acute respiratory illness surveillance characterising influenza and COVID-19 epidemiology in hospitalised adults, 2021-22.
   J Infect. 2024;89:106338.
   PubMed         Abstract available

   J Virol

9. CHEN D, Zhang W, Xiao B, Xu B, et al
   Effect of wild-type vaccine doses on BA.5 hybrid immunity, disease severity, and XBB reinfection risk.
   J Virol. 2024 Nov 5:e0128524. doi: 10.1128/jvi.01285.
   PubMed         Abstract available
10. STEIN SC, Hansen G, Ssebyatika G, Stroh LJ, et al
    A human monoclonal antibody neutralizing SARS-CoV-2 Omicron variants containing the L452R mutation.
    J Virol. 2024 Nov 4:e0122324. doi: 10.1128/jvi.01223.
    PubMed         Abstract available
11. PARRY RH, Lytras S, Petrone ME, Wille M, et al
    No evidence that mutations in SARS-CoV-2 variants of concern derive from homologous fragments in gut microbiota.
    J Virol. 2024 Nov 4:e0146824. doi: 10.1128/jvi.01468.
    PubMed         Abstract available

    Life Sci

12. MARANGI M, Boughattas S, Benslimane F
    Gut microbiome profile to the level species in diarrheic protozoan-carrier patients in Italy.
    Life Sci. 2024 Oct 25:123182. doi: 10.1016/j.lfs.2024.123182.
    PubMed         Abstract available
13. ASHRAF MS, Tuli K, Moiz S, Sharma SK, et al
    AMP kinase: A promising therapeutic drug target for post-COVID-19 complications.
    Life Sci. 2024;359:123202.
    PubMed         Abstract available

    Zhonghua Jie He He Hu Xi Za Zhi

14. LIANG SF, Li WM, Liu D
    [Progress and challenges in clinical diagnosis and treatment of co-existent lung cancer and pulmonary tuberculosis].
    Zhonghua Jie He He Hu Xi Za Zhi. 2024;47:1035-1041.
    PubMed         Abstract available

https://etidioh.wordpress.com/2024/11/10/coronavirus-disease-research-references-by-amedeo-nov-10-24/

#betacoronavirus #cancer #coronavirus #covid #COVID19 #health #mentalHealth #research #sarbecovirus #sarsCov2

1. SELINGER S
   Patients surviving COVID-19 had lower risk for long COVID in the Omicron vs. earlier eras.
   Ann Intern Med. 2024 Nov 5. doi: 10.7326/ANNALS-24-02441.
   PubMed         Abstract available

   BMJ

2. BARRETT A
   Covid-19: Australian inquiry calls for establishment of a national centre for disease control and action to tackle inequities.
   BMJ. 2024;387:q2420.
   PubMed        

   Clin Infect Dis

3. MORTEZAVI M, Sloan A, Singh RSP, Chen LF, et al
   Virologic Response and Safety of Ibuzatrelvir, a Novel SARS-CoV-2 Antiviral, in Adults With COVID-19.
   Clin Infect Dis. 2024 Nov 2:ciae529. doi: 10.1093.
   PubMed         Abstract available

   Int J Infect Dis

4. NAVEED Z, Li J, Wilton J, Naus M, et al
   Healthcare utilization among COVID-19 mRNA vaccine-associated myocarditis cases: a matched retrospective cohort study.
   Int J Infect Dis. 2024 Nov 1:107287. doi: 10.1016/j.ijid.2024.107287.
   PubMed         Abstract available
5. EPSTEIN-SHUMAN A, Hunt JH, Caturegli P, Winguth P, et al
   Autoantibodies Directed Against Interferon Alpha, Nuclear Antigens, Cardiolipin, and Beta 2 Glycoprotein 1 Are Not Induced By SARS-CoV-2 or Associated with Long COVID.
   Int J Infect Dis. 2024 Nov 1:107289. doi: 10.1016/j.ijid.2024.107289.
   PubMed         Abstract available

   Intensive Care Med

6. WANG Y, Hao S, Song J, Zhong M, et al
   Reflections on awake prone positioning in COVID-19: considerations on body inclination, respiratory support, and patient variability.
   Intensive Care Med. 2024 Nov 4. doi: 10.1007/s00134-024-07710.
   PubMed        

   J Infect

7. WANG H, Zhou Y, Chu L, Chen K, et al
   Guardian-driven influenza vaccination intentions for children post-COVID-19 in the 2024-2025 season: The positive spillover effects.
   J Infect. 2024;89:106333.
   PubMed        
8. HO A, McInnes N, Blunsum A, Quinn J, et al
   Near real-time severe acute respiratory illness surveillance characterising influenza and COVID-19 epidemiology in hospitalised adults, 2021-22.
   J Infect. 2024;89:106338.
   PubMed         Abstract available

   J Virol

9. CHEN D, Zhang W, Xiao B, Xu B, et al
   Effect of wild-type vaccine doses on BA.5 hybrid immunity, disease severity, and XBB reinfection risk.
   J Virol. 2024 Nov 5:e0128524. doi: 10.1128/jvi.01285.
   PubMed         Abstract available
10. STEIN SC, Hansen G, Ssebyatika G, Stroh LJ, et al
    A human monoclonal antibody neutralizing SARS-CoV-2 Omicron variants containing the L452R mutation.
    J Virol. 2024 Nov 4:e0122324. doi: 10.1128/jvi.01223.
    PubMed         Abstract available
11. PARRY RH, Lytras S, Petrone ME, Wille M, et al
    No evidence that mutations in SARS-CoV-2 variants of concern derive from homologous fragments in gut microbiota.
    J Virol. 2024 Nov 4:e0146824. doi: 10.1128/jvi.01468.
    PubMed         Abstract available

    Life Sci

12. MARANGI M, Boughattas S, Benslimane F
    Gut microbiome profile to the level species in diarrheic protozoan-carrier patients in Italy.
    Life Sci. 2024 Oct 25:123182. doi: 10.1016/j.lfs.2024.123182.
    PubMed         Abstract available
13. ASHRAF MS, Tuli K, Moiz S, Sharma SK, et al
    AMP kinase: A promising therapeutic drug target for post-COVID-19 complications.
    Life Sci. 2024;359:123202.
    PubMed         Abstract available

    Zhonghua Jie He He Hu Xi Za Zhi

14. LIANG SF, Li WM, Liu D
    [Progress and challenges in clinical diagnosis and treatment of co-existent lung cancer and pulmonary tuberculosis].
    Zhonghua Jie He He Hu Xi Za Zhi. 2024;47:1035-1041.
    PubMed         Abstract available

https://etidioh.wordpress.com/2024/11/10/coronavirus-disease-research-references-by-amedeo-nov-10-24/

#betacoronavirus #cancer #coronavirus #covid #COVID19 #health #mentalHealth #research #sarbecovirus #sarsCov2

1. SELINGER S
   Patients surviving COVID-19 had lower risk for long COVID in the Omicron vs. earlier eras.
   Ann Intern Med. 2024 Nov 5. doi: 10.7326/ANNALS-24-02441.
   PubMed         Abstract available

   BMJ

2. BARRETT A
   Covid-19: Australian inquiry calls for establishment of a national centre for disease control and action to tackle inequities.
   BMJ. 2024;387:q2420.
   PubMed        

   Clin Infect Dis

3. MORTEZAVI M, Sloan A, Singh RSP, Chen LF, et al
   Virologic Response and Safety of Ibuzatrelvir, a Novel SARS-CoV-2 Antiviral, in Adults With COVID-19.
   Clin Infect Dis. 2024 Nov 2:ciae529. doi: 10.1093.
   PubMed         Abstract available

   Int J Infect Dis

4. NAVEED Z, Li J, Wilton J, Naus M, et al
   Healthcare utilization among COVID-19 mRNA vaccine-associated myocarditis cases: a matched retrospective cohort study.
   Int J Infect Dis. 2024 Nov 1:107287. doi: 10.1016/j.ijid.2024.107287.
   PubMed         Abstract available
5. EPSTEIN-SHUMAN A, Hunt JH, Caturegli P, Winguth P, et al
   Autoantibodies Directed Against Interferon Alpha, Nuclear Antigens, Cardiolipin, and Beta 2 Glycoprotein 1 Are Not Induced By SARS-CoV-2 or Associated with Long COVID.
   Int J Infect Dis. 2024 Nov 1:107289. doi: 10.1016/j.ijid.2024.107289.
   PubMed         Abstract available

   Intensive Care Med

6. WANG Y, Hao S, Song J, Zhong M, et al
   Reflections on awake prone positioning in COVID-19: considerations on body inclination, respiratory support, and patient variability.
   Intensive Care Med. 2024 Nov 4. doi: 10.1007/s00134-024-07710.
   PubMed        

   J Infect

7. WANG H, Zhou Y, Chu L, Chen K, et al
   Guardian-driven influenza vaccination intentions for children post-COVID-19 in the 2024-2025 season: The positive spillover effects.
   J Infect. 2024;89:106333.
   PubMed        
8. HO A, McInnes N, Blunsum A, Quinn J, et al
   Near real-time severe acute respiratory illness surveillance characterising influenza and COVID-19 epidemiology in hospitalised adults, 2021-22.
   J Infect. 2024;89:106338.
   PubMed         Abstract available

   J Virol

9. CHEN D, Zhang W, Xiao B, Xu B, et al
   Effect of wild-type vaccine doses on BA.5 hybrid immunity, disease severity, and XBB reinfection risk.
   J Virol. 2024 Nov 5:e0128524. doi: 10.1128/jvi.01285.
   PubMed         Abstract available
10. STEIN SC, Hansen G, Ssebyatika G, Stroh LJ, et al
    A human monoclonal antibody neutralizing SARS-CoV-2 Omicron variants containing the L452R mutation.
    J Virol. 2024 Nov 4:e0122324. doi: 10.1128/jvi.01223.
    PubMed         Abstract available
11. PARRY RH, Lytras S, Petrone ME, Wille M, et al
    No evidence that mutations in SARS-CoV-2 variants of concern derive from homologous fragments in gut microbiota.
    J Virol. 2024 Nov 4:e0146824. doi: 10.1128/jvi.01468.
    PubMed         Abstract available

    Life Sci

12. MARANGI M, Boughattas S, Benslimane F
    Gut microbiome profile to the level species in diarrheic protozoan-carrier patients in Italy.
    Life Sci. 2024 Oct 25:123182. doi: 10.1016/j.lfs.2024.123182.
    PubMed         Abstract available
13. ASHRAF MS, Tuli K, Moiz S, Sharma SK, et al
    AMP kinase: A promising therapeutic drug target for post-COVID-19 complications.
    Life Sci. 2024;359:123202.
    PubMed         Abstract available

    Zhonghua Jie He He Hu Xi Za Zhi

14. LIANG SF, Li WM, Liu D
    [Progress and challenges in clinical diagnosis and treatment of co-existent lung cancer and pulmonary tuberculosis].
    Zhonghua Jie He He Hu Xi Za Zhi. 2024;47:1035-1041.
    PubMed         Abstract available

https://etidioh.wordpress.com/2024/11/10/coronavirus-disease-research-references-by-amedeo-nov-10-24/

#betacoronavirus #cancer #coronavirus #covid #COVID19 #health #mentalHealth #research #sarbecovirus #sarsCov2

1. SELINGER S
   Patients surviving COVID-19 had lower risk for long COVID in the Omicron vs. earlier eras.
   Ann Intern Med. 2024 Nov 5. doi: 10.7326/ANNALS-24-02441.
   PubMed         Abstract available

   BMJ

2. BARRETT A
   Covid-19: Australian inquiry calls for establishment of a national centre for disease control and action to tackle inequities.
   BMJ. 2024;387:q2420.
   PubMed        

   Clin Infect Dis

3. MORTEZAVI M, Sloan A, Singh RSP, Chen LF, et al
   Virologic Response and Safety of Ibuzatrelvir, a Novel SARS-CoV-2 Antiviral, in Adults With COVID-19.
   Clin Infect Dis. 2024 Nov 2:ciae529. doi: 10.1093.
   PubMed         Abstract available

   Int J Infect Dis

4. NAVEED Z, Li J, Wilton J, Naus M, et al
   Healthcare utilization among COVID-19 mRNA vaccine-associated myocarditis cases: a matched retrospective cohort study.
   Int J Infect Dis. 2024 Nov 1:107287. doi: 10.1016/j.ijid.2024.107287.
   PubMed         Abstract available
5. EPSTEIN-SHUMAN A, Hunt JH, Caturegli P, Winguth P, et al
   Autoantibodies Directed Against Interferon Alpha, Nuclear Antigens, Cardiolipin, and Beta 2 Glycoprotein 1 Are Not Induced By SARS-CoV-2 or Associated with Long COVID.
   Int J Infect Dis. 2024 Nov 1:107289. doi: 10.1016/j.ijid.2024.107289.
   PubMed         Abstract available

   Intensive Care Med

6. WANG Y, Hao S, Song J, Zhong M, et al
   Reflections on awake prone positioning in COVID-19: considerations on body inclination, respiratory support, and patient variability.
   Intensive Care Med. 2024 Nov 4. doi: 10.1007/s00134-024-07710.
   PubMed        

   J Infect

7. WANG H, Zhou Y, Chu L, Chen K, et al
   Guardian-driven influenza vaccination intentions for children post-COVID-19 in the 2024-2025 season: The positive spillover effects.
   J Infect. 2024;89:106333.
   PubMed        
8. HO A, McInnes N, Blunsum A, Quinn J, et al
   Near real-time severe acute respiratory illness surveillance characterising influenza and COVID-19 epidemiology in hospitalised adults, 2021-22.
   J Infect. 2024;89:106338.
   PubMed         Abstract available

   J Virol

9. CHEN D, Zhang W, Xiao B, Xu B, et al
   Effect of wild-type vaccine doses on BA.5 hybrid immunity, disease severity, and XBB reinfection risk.
   J Virol. 2024 Nov 5:e0128524. doi: 10.1128/jvi.01285.
   PubMed         Abstract available
10. STEIN SC, Hansen G, Ssebyatika G, Stroh LJ, et al
    A human monoclonal antibody neutralizing SARS-CoV-2 Omicron variants containing the L452R mutation.
    J Virol. 2024 Nov 4:e0122324. doi: 10.1128/jvi.01223.
    PubMed         Abstract available
11. PARRY RH, Lytras S, Petrone ME, Wille M, et al
    No evidence that mutations in SARS-CoV-2 variants of concern derive from homologous fragments in gut microbiota.
    J Virol. 2024 Nov 4:e0146824. doi: 10.1128/jvi.01468.
    PubMed         Abstract available

    Life Sci

12. MARANGI M, Boughattas S, Benslimane F
    Gut microbiome profile to the level species in diarrheic protozoan-carrier patients in Italy.
    Life Sci. 2024 Oct 25:123182. doi: 10.1016/j.lfs.2024.123182.
    PubMed         Abstract available
13. ASHRAF MS, Tuli K, Moiz S, Sharma SK, et al
    AMP kinase: A promising therapeutic drug target for post-COVID-19 complications.
    Life Sci. 2024;359:123202.
    PubMed         Abstract available

    Zhonghua Jie He He Hu Xi Za Zhi

14. LIANG SF, Li WM, Liu D
    [Progress and challenges in clinical diagnosis and treatment of co-existent lung cancer and pulmonary tuberculosis].
    Zhonghua Jie He He Hu Xi Za Zhi. 2024;47:1035-1041.
    PubMed         Abstract available

https://etidioh.wordpress.com/2024/11/10/coronavirus-disease-research-references-by-amedeo-nov-10-24/

#betacoronavirus #cancer #coronavirus #covid #COVID19 #health #mentalHealth #research #sarbecovirus #sarsCov2

1. NAKASHIMA M, Nobori H, Kuroda T, Shimba A, et al
   Oral 3CL protease inhibitor ensitrelvir suppressed SARS-CoV-2 shedding and infection in a hamster aerosol transmission model.
   Antiviral Res. 2024 Oct 28:106026. doi: 10.1016/j.antiviral.2024.106026.
   PubMed         Abstract available

   BMJ

2. DOWNAR J, Close E, Young JE, White BP, et al
   Assisted dying: balancing safety with access.
   BMJ. 2024;387:q2382.
   PubMed        

   Clin Infect Dis

3. BHIMRAJ A, Falck-Ytter Y, Kim AY, Li JZ, et al
   2024 Clinical Practice Guideline Update by the Infectious Diseases Society of America on the Management of COVID-19: Anti-SARS-CoV-2 Neutralizing Antibody Pemivibart for Pre-exposure Prophylaxis.
   Clin Infect Dis. 2024 Oct 29:ciae435. doi: 10.1093.
   PubMed         Abstract available

   Infect Control Hosp Epidemiol

4. QADDOURA A, McQuiston M, Tyrrell G, Croxen M, et al
   Analysis of invasive group A streptococcal puerperal sepsis in Calgary, Alberta: clinical consequences and policy implications.
   Infect Control Hosp Epidemiol. 2024;45:1-4.
   PubMed         Abstract available

   J Med Virol

5. SONG K, Hasan A, Hao W, Wu Y, et al
   Stimulator of interferon genes (STING) inhibits coronavirus infection by disrupting viral replication organelles.
   J Med Virol. 2024;96:e70020.
   PubMed         Abstract available
6. YILDIZ Y, Yasar E, Ozturk E, Karakan MS, et al
   Heterologous Versus Homologous COVID-19 Boosters: Immune Response Outcomes in Renal Transplant Recipients.
   J Med Virol. 2024;96:e70030.
   PubMed         Abstract available

   J Virol

7. LIU X, Zhang M, Yin L, Kang L, et al
   PEDV evades MHC-I-related immunity through nsp1-mediated NLRC5 translation inhibition.
   J Virol. 2024 Oct 31:e0142124. doi: 10.1128/jvi.01421.
   PubMed         Abstract available
8. SHI L, Duan Y, Cao L, Zhang Y, et al
   PF-00835231 broadly inhibits swine Alpha-coronavirus, including emerging SADS-CoV.
   J Virol. 2024 Oct 31:e0130324. doi: 10.1128/jvi.01303.
   PubMed         Abstract available
9. HOFFMANN M, Kleine-Weber H, Graichen L, Nehlmeier I, et al
   Acquisition of a multibasic cleavage site does not increase MERS-CoV entry into Calu-3 human lung cells.
   J Virol. 2024 Oct 29:e0130524. doi: 10.1128/jvi.01305.
   PubMed         Abstract available

   JAMA

10. TADROUS M, Callaway Kim K, Hernandez I, Rothenberger SD, et al
    Differences in Drug Shortages in the US and Canada.
    JAMA. 2024 Oct 31. doi: 10.1001/jama.2024.17688.
    PubMed         Abstract available

    Lancet Infect Dis

11. PASCAL G
    COVID-19 in South Asia.
    Lancet Infect Dis. 2024 Oct 22:S1473-3099(24)00723.
    PubMed        
12. OKADA Y, Kumagai Y, Okura I, Otsuki M, et al
    Immunogenicity of a booster dose of a bivalent (Asp614Gly and omicron BA.4/5 variant) self-amplifying mRNA SARS-CoV-2 booster vaccine versus the BNT162b2 omicron BA.4/5 mRNA vaccine: a randomised phase 3 trial.
    Lancet Infect Dis. 2024 Oct 23:S1473-3099(24)00565.
    PubMed         Abstract available

    Life Sci

13. YU LC
    Gastrointestinal pathophysiology in long COVID: Exploring roles of microbiota dysbiosis and serotonin dysregulation in post-infectious bowel symptoms.
    Life Sci. 2024;358:123153.
    PubMed         Abstract available
14. WANG N, Fan H, Wang Y, Shu C, et al
    The hybrid immunity defined by weaker immune imprinting of people living with HIV has a stronger neutralizing response against Omicron variants. A suggested explanation for fewer symptoms in people living with HIV after SARS-CoV-2 variants breakthroug
    Life Sci. 2024 Oct 29:123197. doi: 10.1016/j.lfs.2024.123197.
    PubMed         Abstract available

    MMWR Morb Mortal Wkly Rep

15. BELL J, Meng L, Barbre K, Wong E, et al
    Influenza and COVID-19 Vaccination Coverage Among Health Care Personnel – National Healthcare Safety Network, United States, 2023-24 Respiratory Virus Season.
    MMWR Morb Mortal Wkly Rep. 2024;73:966-972.
    PubMed         Abstract available
16. JONES CE, Danovaro-Holliday MC, Mwinnyaa G, Gacic-Dobo M, et al
    Routine Vaccination Coverage – Worldwide, 2023.
    MMWR Morb Mortal Wkly Rep. 2024;73:978-984.
    PubMed         Abstract available

    N Engl J Med

17. LITWINSKA-KMIECIK A, Mrowczynski K
    Postacute Sequelae of SARS-CoV-2 Infection in Several Eras.
    N Engl J Med. 2024;391:1658-1659.
    PubMed        
18. YANG C, Tebbutt SJ
    Postacute Sequelae of SARS-CoV-2 Infection in Several Eras.
    N Engl J Med. 2024;391:1659.
    PubMed        
19. XIE Y, Al-Aly Z
    Postacute Sequelae of SARS-CoV-2 Infection in Several Eras. Reply.
    N Engl J Med. 2024;391:1659-1660.
    PubMed        

    Nature

20. LIU P, Huang ML, Guo H, McCallum M, et al
    Design of customized coronavirus receptors.
    Nature. 2024 Oct 30. doi: 10.1038/s41586-024-08121.
    PubMed         Abstract available

    Science

21. LONG K
    Keeping outbreaks at bayCrisis Averted: The Hidden Science of Fighting Outbreaks Caitlin Rivers Viking, 2024. 320 pp.
    Science. 2024;386:499.
    PubMed         Abstract available
22. KUPFERSCHMIDT K
    You won’t believe this.
    Science. 2024;386:483-485.
    PubMed         Abstract available

https://etidioh.wordpress.com/2024/11/03/coronavirus-disease-research-references-by-amedeo-nov-3-24/

#betacoronavirus #coronavirus #covid #COVID19 #health #research #sarbecovirus #sarsCov2 #science

1. NAKASHIMA M, Nobori H, Kuroda T, Shimba A, et al
   Oral 3CL protease inhibitor ensitrelvir suppressed SARS-CoV-2 shedding and infection in a hamster aerosol transmission model.
   Antiviral Res. 2024 Oct 28:106026. doi: 10.1016/j.antiviral.2024.106026.
   PubMed         Abstract available

   BMJ

2. DOWNAR J, Close E, Young JE, White BP, et al
   Assisted dying: balancing safety with access.
   BMJ. 2024;387:q2382.
   PubMed        

   Clin Infect Dis

3. BHIMRAJ A, Falck-Ytter Y, Kim AY, Li JZ, et al
   2024 Clinical Practice Guideline Update by the Infectious Diseases Society of America on the Management of COVID-19: Anti-SARS-CoV-2 Neutralizing Antibody Pemivibart for Pre-exposure Prophylaxis.
   Clin Infect Dis. 2024 Oct 29:ciae435. doi: 10.1093.
   PubMed         Abstract available

   Infect Control Hosp Epidemiol

4. QADDOURA A, McQuiston M, Tyrrell G, Croxen M, et al
   Analysis of invasive group A streptococcal puerperal sepsis in Calgary, Alberta: clinical consequences and policy implications.
   Infect Control Hosp Epidemiol. 2024;45:1-4.
   PubMed         Abstract available

   J Med Virol

5. SONG K, Hasan A, Hao W, Wu Y, et al
   Stimulator of interferon genes (STING) inhibits coronavirus infection by disrupting viral replication organelles.
   J Med Virol. 2024;96:e70020.
   PubMed         Abstract available
6. YILDIZ Y, Yasar E, Ozturk E, Karakan MS, et al
   Heterologous Versus Homologous COVID-19 Boosters: Immune Response Outcomes in Renal Transplant Recipients.
   J Med Virol. 2024;96:e70030.
   PubMed         Abstract available

   J Virol

7. LIU X, Zhang M, Yin L, Kang L, et al
   PEDV evades MHC-I-related immunity through nsp1-mediated NLRC5 translation inhibition.
   J Virol. 2024 Oct 31:e0142124. doi: 10.1128/jvi.01421.
   PubMed         Abstract available
8. SHI L, Duan Y, Cao L, Zhang Y, et al
   PF-00835231 broadly inhibits swine Alpha-coronavirus, including emerging SADS-CoV.
   J Virol. 2024 Oct 31:e0130324. doi: 10.1128/jvi.01303.
   PubMed         Abstract available
9. HOFFMANN M, Kleine-Weber H, Graichen L, Nehlmeier I, et al
   Acquisition of a multibasic cleavage site does not increase MERS-CoV entry into Calu-3 human lung cells.
   J Virol. 2024 Oct 29:e0130524. doi: 10.1128/jvi.01305.
   PubMed         Abstract available

   JAMA

10. TADROUS M, Callaway Kim K, Hernandez I, Rothenberger SD, et al
    Differences in Drug Shortages in the US and Canada.
    JAMA. 2024 Oct 31. doi: 10.1001/jama.2024.17688.
    PubMed         Abstract available

    Lancet Infect Dis

11. PASCAL G
    COVID-19 in South Asia.
    Lancet Infect Dis. 2024 Oct 22:S1473-3099(24)00723.
    PubMed        
12. OKADA Y, Kumagai Y, Okura I, Otsuki M, et al
    Immunogenicity of a booster dose of a bivalent (Asp614Gly and omicron BA.4/5 variant) self-amplifying mRNA SARS-CoV-2 booster vaccine versus the BNT162b2 omicron BA.4/5 mRNA vaccine: a randomised phase 3 trial.
    Lancet Infect Dis. 2024 Oct 23:S1473-3099(24)00565.
    PubMed         Abstract available

    Life Sci

13. YU LC
    Gastrointestinal pathophysiology in long COVID: Exploring roles of microbiota dysbiosis and serotonin dysregulation in post-infectious bowel symptoms.
    Life Sci. 2024;358:123153.
    PubMed         Abstract available
14. WANG N, Fan H, Wang Y, Shu C, et al
    The hybrid immunity defined by weaker immune imprinting of people living with HIV has a stronger neutralizing response against Omicron variants. A suggested explanation for fewer symptoms in people living with HIV after SARS-CoV-2 variants breakthroug
    Life Sci. 2024 Oct 29:123197. doi: 10.1016/j.lfs.2024.123197.
    PubMed         Abstract available

    MMWR Morb Mortal Wkly Rep

15. BELL J, Meng L, Barbre K, Wong E, et al
    Influenza and COVID-19 Vaccination Coverage Among Health Care Personnel – National Healthcare Safety Network, United States, 2023-24 Respiratory Virus Season.
    MMWR Morb Mortal Wkly Rep. 2024;73:966-972.
    PubMed         Abstract available
16. JONES CE, Danovaro-Holliday MC, Mwinnyaa G, Gacic-Dobo M, et al
    Routine Vaccination Coverage – Worldwide, 2023.
    MMWR Morb Mortal Wkly Rep. 2024;73:978-984.
    PubMed         Abstract available

    N Engl J Med

17. LITWINSKA-KMIECIK A, Mrowczynski K
    Postacute Sequelae of SARS-CoV-2 Infection in Several Eras.
    N Engl J Med. 2024;391:1658-1659.
    PubMed        
18. YANG C, Tebbutt SJ
    Postacute Sequelae of SARS-CoV-2 Infection in Several Eras.
    N Engl J Med. 2024;391:1659.
    PubMed        
19. XIE Y, Al-Aly Z
    Postacute Sequelae of SARS-CoV-2 Infection in Several Eras. Reply.
    N Engl J Med. 2024;391:1659-1660.
    PubMed        

    Nature

20. LIU P, Huang ML, Guo H, McCallum M, et al
    Design of customized coronavirus receptors.
    Nature. 2024 Oct 30. doi: 10.1038/s41586-024-08121.
    PubMed         Abstract available

    Science

21. LONG K
    Keeping outbreaks at bayCrisis Averted: The Hidden Science of Fighting Outbreaks Caitlin Rivers Viking, 2024. 320 pp.
    Science. 2024;386:499.
    PubMed         Abstract available
22. KUPFERSCHMIDT K
    You won’t believe this.
    Science. 2024;386:483-485.
    PubMed         Abstract available

https://etidioh.wordpress.com/2024/11/03/coronavirus-disease-research-references-by-amedeo-nov-3-24/

#betacoronavirus #coronavirus #covid #COVID19 #health #research #sarbecovirus #sarsCov2 #science

Source: Journal of Virology, https://journals.asm.org/doi/10.1128/jvi.01305-24

ABSTRACT
Human-to-human transmission of the highly pathogenic Middle East respiratory syndrome coronavirus (MERS-CoV) is currently inefficient. However, there is concern that the virus might mutate and thereby increase its transmissibility and thus pandemic potential. The pandemic SARS-CoV-2 depends on a highly cleavable furin motif at the S1/S2 site of the viral spike (S) protein for efficient lung cell entry, transmission, and pathogenicity. Here, by employing pseudotyped particles, we investigated whether augmented cleavage at the S1/S2 site also increases MERS-CoV entry into Calu-3 human lung cells. We report that polymorphism T746K at the S1/S2 cleavage site or optimization of the furin motif increases S protein cleavage but not lung cell entry. These findings suggest that, unlike what has been reported for SARS-CoV-2, a highly cleavable S1/S2 site might not augment MERS-CoV infectivity for human lung cells.

____

https://etidioh.wordpress.com/2024/10/29/acquisition-of-a-multibasic-cleavage-site-does-not-increase-mers-cov-entry-into-calu-3-human-lung-cells/

#abstract #betacoronavirus #covid #COVID19 #health #merbecovirus #mersCov #research #sarbecovirus #sarsCov2 #science #vaccine

Source: Journal of Virology, https://journals.asm.org/doi/10.1128/jvi.01305-24

ABSTRACT
Human-to-human transmission of the highly pathogenic Middle East respiratory syndrome coronavirus (MERS-CoV) is currently inefficient. However, there is concern that the virus might mutate and thereby increase its transmissibility and thus pandemic potential. The pandemic SARS-CoV-2 depends on a highly cleavable furin motif at the S1/S2 site of the viral spike (S) protein for efficient lung cell entry, transmission, and pathogenicity. Here, by employing pseudotyped particles, we investigated whether augmented cleavage at the S1/S2 site also increases MERS-CoV entry into Calu-3 human lung cells. We report that polymorphism T746K at the S1/S2 cleavage site or optimization of the furin motif increases S protein cleavage but not lung cell entry. These findings suggest that, unlike what has been reported for SARS-CoV-2, a highly cleavable S1/S2 site might not augment MERS-CoV infectivity for human lung cells.

____

https://etidioh.wordpress.com/2024/10/29/acquisition-of-a-multibasic-cleavage-site-does-not-increase-mers-cov-entry-into-calu-3-human-lung-cells/

#abstract #betacoronavirus #covid #COVID19 #health #merbecovirus #mersCov #research #sarbecovirus #sarsCov2 #science #vaccine

Source: Journal of Virology, https://journals.asm.org/doi/10.1128/jvi.01305-24

ABSTRACT
Human-to-human transmission of the highly pathogenic Middle East respiratory syndrome coronavirus (MERS-CoV) is currently inefficient. However, there is concern that the virus might mutate and thereby increase its transmissibility and thus pandemic potential. The pandemic SARS-CoV-2 depends on a highly cleavable furin motif at the S1/S2 site of the viral spike (S) protein for efficient lung cell entry, transmission, and pathogenicity. Here, by employing pseudotyped particles, we investigated whether augmented cleavage at the S1/S2 site also increases MERS-CoV entry into Calu-3 human lung cells. We report that polymorphism T746K at the S1/S2 cleavage site or optimization of the furin motif increases S protein cleavage but not lung cell entry. These findings suggest that, unlike what has been reported for SARS-CoV-2, a highly cleavable S1/S2 site might not augment MERS-CoV infectivity for human lung cells.

____

https://etidioh.wordpress.com/2024/10/29/acquisition-of-a-multibasic-cleavage-site-does-not-increase-mers-cov-entry-into-calu-3-human-lung-cells/

#abstract #betacoronavirus #merbecovirus #mersCov #research #sarbecovirus #sarsCov2

Source: Journal of Virology, https://journals.asm.org/doi/10.1128/jvi.01305-24

ABSTRACT
Human-to-human transmission of the highly pathogenic Middle East respiratory syndrome coronavirus (MERS-CoV) is currently inefficient. However, there is concern that the virus might mutate and thereby increase its transmissibility and thus pandemic potential. The pandemic SARS-CoV-2 depends on a highly cleavable furin motif at the S1/S2 site of the viral spike (S) protein for efficient lung cell entry, transmission, and pathogenicity. Here, by employing pseudotyped particles, we investigated whether augmented cleavage at the S1/S2 site also increases MERS-CoV entry into Calu-3 human lung cells. We report that polymorphism T746K at the S1/S2 cleavage site or optimization of the furin motif increases S protein cleavage but not lung cell entry. These findings suggest that, unlike what has been reported for SARS-CoV-2, a highly cleavable S1/S2 site might not augment MERS-CoV infectivity for human lung cells.

____

https://etidioh.wordpress.com/2024/10/29/acquisition-of-a-multibasic-cleavage-site-does-not-increase-mers-cov-entry-into-calu-3-human-lung-cells/

#abstract #betacoronavirus #merbecovirus #mersCov #research #sarbecovirus #sarsCov2